

### **Detailed Clinical Model Specification**

# Adverse Reaction Version 3.1

22 December 2011
Approved for External Release

#### **National E-Health Transition Authority Ltd**

Level 25 56 Pitt Street Sydney NSW 2000 Australia www.nehta.gov.au

#### Disclaimer

NEHTA makes the information and other material ("Information") in this document available in good faith but without any representation or warranty as to its accuracy or completeness. NEHTA cannot accept any responsibility for the consequences of any use of the Information. As the Information is of a general nature only, it is up to any person using or relying on the Information to ensure that it is accurate, complete and suitable for the circumstances of its use.

#### **Document Control**

This document is maintained in electronic form and is uncontrolled in printed form. It is the responsibility of the user to verify that this copy is the latest revision.

#### Copyright © 2011 National E-Health Transition Authority Ltd. (NEHTA)

This document contains information which is protected by copyright. All Rights Reserved. No part of this work may be reproduced or used in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems—without the permission of NEHTA. All copies of this document must include the copyright and other information contained on this page.

ii v 3.1

nehta Document Information

### **Document Information**

#### **Document owner**

#### **Document Owner**

The National Clinical Terminology and Information Service

### **Change history**

Version	Date	Comments
1.0	29 Jun 2007	Initial public release
1.1	29 Feb 2008	Minor typographical corrections and wording changes in Introduction
2.0	7 Sep 2009	Updated to incorporate changes made in the version 2.0 of the Discharge Summary Specification.
3.0	24 Aug 2011	New version created in accordance with the archetype from <u>NEHTA Clinical Knowledge Manager</u> <sup>1</sup> .
3.1	22 Dec 2011	This version of the specification is published to support the Structured Content Specifications published (at the end of 2011) that use the versions of the DCMs included in this specification. Changes to the DCMs, included in this specification, are primarily to support the Consolidated View in the PCEHR.

#### **Related documents**

Name	Version/Release Date
NEHTA Acronyms, Abbreviations & Glossary of Terms	Version 1.2, Issued 25 May 2005
Participation Data Specification	Version 3.2, Issued 20 July 2011

### **Included Detailed Clinical Models**

This specification contains the following Detailed Clinical Models:

- 1. Adverse Reaction, version 5.1
- 2. Exclusion Statement Adverse Reactions, version 1.2

<sup>1</sup> http://dcm.nehta.org.au/ckm

This page is intentionally left blank.

iv v 3.1

nehta Acknowledgements

# **Acknowledgements**

NEHTA would like to thank the following organisations and individuals for their contribution to these data specifications:

- · Standards Australia;
- · Members of the Australian DataTypes Project;
- · Australian Institute of Health and Welfare; and
- · Ocean Informatics.

This page is intentionally left blank.

vi v 3.1

# **Table of Contents**

1. Introduction	
1.1. Purpose and Scope	1
1.2. Intended Audience	1
1.3. Background	1
1.4. Terminology	
2. Adverse Reaction Detailed Clinical Model	3
2.1. Purpose	
2.2. Use	
2.3. Misuse	
2.4. UML Class Diagram	
2.5. ADVERSE REACTION	
2.6. Substance/Agent	
2.7. Substance/Agent Values	
2.7. Substance/Agent values	
2.9. Adverse Reaction Comment	
2.10. REACTION EVENT	
2.11. Specific Substance/Agent	
2.12. Manifestation	
2.13. Clinical Manifestation Values	
2.14. Reaction Type	
2.15. Adverse Reaction Certainty	
2.16. Adverse Reaction Certainty Values	
2.17. Reaction Description	24
2.18. Reaction Onset Date	25
2.19. Duration of Reaction	26
2.20. ANATOMICAL LOCATION	27
2.21. SPECIFIC LOCATION	28
2.22. Anatomical Location Name	29
2.23. Body Structure Foundation Reference Set	
2.24. Side	
2.25. Laterality Reference Set	
2.26. Numerical Identifier	
2.27. Anatomical Plane	
2.28. RELATIVE LOCATION	
2.29. Identified Landmark	
2.30. Anatomical Location Aspect	
2.31. Distance From Landmark	
2.32. Anatomical Location Description	
2.33. Visual Markings/Orientation	
· · · · · · · · · · · · · · · · · · ·	
2.35. Exposure Description	
2.36. Earliest Exposure	
2.37. Duration of Exposure	
2.38. ADDITIONAL EXPOSURE DETAIL	
2.39. AMOUNT OF MEDICATION	
2.40. Quantity	
2.41. Dose Unit	
2.42. Dose Unit Reference Set	
2.43. Quantity Description	
2.44. TIMING	
2.45. Intervention Frequency Range	54
2.46. Intervention Interval Range	
2.47. Intervention Time	56
2.48. Intervention Day of Week	57
2.49. Intervention Day of Month	58

	2.50. Intervention Date		
	2.51. MEDICATION ADMINISTRATION	60	C
	2.52. Route	. 62	2
	2.53. Route of Administration Reference Set	6	3
	2.54. Anatomical Site	64	4
	2.55. Body Structure Foundation Reference Set	6	5
	2.56. Medication Delivery Method		
	2.57. Dose Duration		
	2.58. Intravenous Administration Details		
	2.59. Clinical Management Description		
	2.60. Multimedia		
	2.61. Reporting Details		
	2.62. Adverse Reaction Event Comment		
	2.63. Reaction Reported		
	2.64. Adverse Reaction Report		
	2.65. Supporting Clinical Record Information		
	2.66. INFORMATION PROVIDER		
	2.67. SUBJECT		
	2.68. Adverse Reaction Instance Identifier		
	2.69. LINK		
	2.70. Link Nature	_	
	2.71. Link Nature Values		
	2.71. Link Nature values 2.72. Link Role		
	2.73. Link Role Values		
	2.74. Link Role Values		
,	2.75. Detailed Clinical Model Identifier		
٥.	Exclusion Statement - Adverse Reactions Detailed Clinical Model		
	3.1. Purpose		
	3.2. Use		
	3.3. UML Class Diagram		
	3.4. EXCLUSION STATEMENT - ADVERSE REACTIONS		
	3.5. Global Statement		
	3.6. Global Statement Values		
	3.7. No Known Adverse Reaction to		
	3.8. No Known Allergic Reaction to		
	3.9. No Known Hypersensitivity Reaction to		
	3.10. No Known Intolerance to		
	3.11. INFORMATION PROVIDER	10	
	3.12. SUBJECT		
	3.13. Exclusion Statement - Adverse Reactions Instance Identifier	10	5
	3.14. LINK	100	õ
	3.15. Link Nature	10	7
	3.16. Link Nature Values		
	3.17. Link Role	110	C
	3.18. Link Role Values	112	2
	3.19. Link Target	114	4
	3.20. Detailed Clinical Model Identifier		
١.	Known Issues	11	7
	Specification Guide for Use		
	B.1. Overview		
	B.2. The Structured Content Specification Metamodel		
	Context		
	Content		
	Section		
	Data Group		
	Participation		
	Choice		
	Data Element		
	Data Licition	124	-

Value Domain 1	22
B.3. Icon Legend 1	22
Metadata Types Legend 1	
Data Types Legend 1	23
Keywords Legend 1	27
Obligation Legend 1	28
B.4. Information Model Specification Parts Legends	29
Data Hierarchy 1	
Chapter Name1	29
Identification Section Legend1	30
Definition Section Legend1	30
Value Domain Section Legend 1	31
Usage Section Legend1	31
Relationships Section Legend1	32
C. Change History	33
C.1. Changes Introduced in this Version	
Reference List	
Index	41

This page is intentionally left blank.

x v 3.1

nehta Introduction

# 1 Introduction

# 1.1 Purpose and Scope

This detailed clinical model (DCM) specification forms part of a suite of data specifications that the National E-Health Transition Authority (NEHTA) is developing for the Australian health informatics community. The suite comprises specifications for a range of health topics (represented as data groups), which are considered to be the most critical to support the work programme given to NEHTA and to realise the benefits derived from Level 4 (semantic) interoperability in the Australian healthcare setting.

NEHTA values your questions and comments about this document. Please direct your questions or feedback to <u>clinicalinformation@nehta.gov.au</u>.

### 1.2 Intended Audience

This document is intended to be read by jurisdictional information and communication technology (ICT) managers, clinicians involved in clinical information system specifications, software architects and developers, and implementers of clinical information systems in various healthcare settings.

It is reasonably technical in nature and expects the audience to be familiar with the language of health data specification and have some familiarity with health information standards and specifications. Definitions and examples are provided to clarify relevant terminology usage and intent.

# 1.3 Background

There are several e-health priority areas to be addressed by NEHTA specifications. One area of priority is identification of the data to be communicated and its structure. NEHTA is addressing this through data specifications, which detail the data elements (logically grouped) and their associated value domains.

Data specifications need to be independent of messaging formats. They are concerned with providing an information framework in which to achieve semantic interoperability.

Data specifications have been developed:

- · Based on jurisdiction and clinician identified priorities;
- Specifically to suit the Australian model for a shared electronic health record (EHR);
- To define collections of related information, e.g. event summaries, data groups, data elements;
- · To allow for expansion and extension as electronic systems mature;
- So they are human readable (with information enhanced by the hierarchical structure);
- · Incorporating clinical examples of use to enhance utility and adoption; and
- To provide a set of clinical terminologies, specific to the requirements of the Australian healthcare system.

Whilst the Personally Controlled Electronic Health Record (PCEHR) System is referred to in these documents, the implementation of the PCEHR System is not dealt with here.

<sup>&</sup>lt;sup>1</sup>Level 4 interoperability is described in [WALJ2005a].

# 1.4 Terminology

NEHTA, through the National Clinical Terminology and Information Service (NCTIS), is defining a national approach to clinical terminology. Consistent and accurate articulation and interpretation of clinical terms is critical to the process of safe exchange.

The Systematized Nomenclature of Medicine - Clinical Terms<sup>®</sup> (SNOMED CT<sup>® 2</sup>) has been recommended by NEHTA and endorsed by the Australian, state and territory governments as the preferred clinical terminology for Australia, and is now freely available for e-health software developers to use in their Australian products under International Health Terminology Standards Development Organisation (IHTSDO) licensing arrangements.

While NEHTA's achievement of a national standard clinical terminology is based on SNOMED CT as the foundational resource, local variations and customisation of terms relevant to the Australian healthcare sector will be incorporated. SNOMED CT Australian Release (SNOMED CT-AU) is the Australian extension to SNOMED CT; the integrated national release of SNOMED CT for implementation in Australian deployed clinical IT systems. NEHTA is also developing the Australian Medicines Terminology (AMT) as the designated clinical terminology for medicines available in Australia. The AMT will provide a consistent approach to the identification and naming of medicines, to support medicines management and activity across the Australian healthcare domain. The AMT will be integrated with SNOMED CT-AU in the near future.

Reference sets listed as value domains within this document have been developed taking into account data element and data group definitions, as well as how they align and complement the SNOMED CT concept model. For further information regarding terminology and the development of reference sets please visit <a href="http://www.nehta.gov.au/our-work/clinical-terminology">http://www.nehta.gov.au/our-work/clinical-terminology</a> and direct your questions or feedback to <a href="mailto:terminologies@nehta.gov.au">terminologies@nehta.gov.au</a>.

<sup>&</sup>lt;sup>2</sup>SNOMED CT<sup>®</sup> is a registered trademark of the International Health Terminology Standards Development Organisation.

# 2 Adverse Reaction Detailed Clinical Model

This chapter describes version 5.1 of the Adverse Reaction Detailed Clinical Model.

# 2.1 Purpose

To record health information that will inform a clinical assessment of the propensity of an individual for a future reaction to a substance, class of substance or agent.

To record information about exposure events to a substance, building up a persisting and evolving summary over time.

To record information about any adverse reaction, including:

- · immune mediated reactions Types I-IV (including allergic reactions and hypersensitivities), and
- non-immune mediated reactions (including pseudoallergic reactions, side effects, intolerances, drug toxicities (e.g. Gentamicin), drug-drug interactions, food-drug interactions, drug-disease interactions and idiosyncratic reactions).

### 2.2 Use

Use to record all information about adverse reactions (including allergic reactions) that are required to support direct clinical care of an individual, safe exchange of information about adverse reactions and to enable computerised knowledge-based activities such as clinical decision support and alerts.

Use to provide a single place within the health record to record a range of clinical statements about adverse reactions, including:

- record cumulative information about each exposure to a known substance, class of substance or agent; and
- record a clinician's opinion that administration of, or exposure to, a substance or agent is absolutely contraindicated.

Can also be used to record an individual's reflections on their adverse reactions.

Use to record the information about an adverse reaction that might be exchanged with other systems, including as part of an adverse reaction report sent to statutory authorities. It is likely that a formal adverse reaction report will require additional information that will be captured in the health record using other data groups, for example medication and problem/diagnosis etc.

This data group has been designed to allow recording of information about a more generic substance, class of substance or agent, and then allow more specific details to be recorded including identification of the specific substance on a per exposure basis, including links to other parts of the health record where further details may be located. Note: it is possible on second or subsequent exposures to a previously identified substance for a reaction not to occur and this data group allows for these events to be closely linked in a way that will assist in determining if the adverse reaction has been incorrectly identified.

In addition, it is anticipated that in some very specific clinical situations, such as immunologist assessment or for use in clinical trials, more information about the adverse reaction may be required. Additional details can be added as cluster data groups using the *Additional Exposure Detail* and *Additional Reaction Details* 

slots. Similarly, additional details that are required only for reporting can be added using the *Reporting Details* slot.

The act of recording an adverse reaction in the health record implies there is a potential hazard for the individual if they are exposed to the same substance/agent in the future - a relative contraindication. If a clinician considers that it is not safe for the individual to be deliberately re-exposed to the substance/agent again, for example, following a manifestation of anaphylaxis, the *Absolute Contraindication* data flag should be recorded as True. Note: Conversely, a statement about severity of propensity (with possible values such as mild, moderate and severe) has deliberately not been modelled explicitly. Predicting or estimating the grade of possible severity of a future reaction is not safe to record and persist in data, except where it is absolutely clear that the risk of deliberate re-exposure is unacceptable and highly likely to cause significant harm, such as a previous manifestation of anaphylaxis, and in this case the *Absolute Contraindication* data flag should be used.

Valuable first-level information that could be presented to the clinician when they need to assess propensity for future reactions are:


- statements about previous clinical manifestations following exposure,
- · source of the information/reporter, and
- · a flag for absolute contraindication.

Second-level information can be drawn from each exposure event and links to additional detailed information such as history, examination and diagnoses stored elsewhere in the record, if it is available.

### 2.3 Misuse

- Not to be used for recording the absence (or negative presence) of a reaction to 'any substances' or to identified substances – use the EVALUATION.exclusion family of data groups to express a positive statement of exclusion.
- 2. Not to be used for recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absent\_information family of data group to record a positive statement of absent information about adverse reactions was able to be obtained, for example, if a non-cooperative patient refuses to answer questions.
- 3. Not to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use or mistakes/errors made in administration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose, etc.
- 4. Not to be used for recording alerts.

# 2.4 UML Class Diagram



The figure represents the data hierarchy of the Detailed Clinical Model as a UML 2.0 class diagram. The diagram displays data groups and data elements, together with their names, data types and multiplicities. Data elements are displayed as attributes. Data groups are displayed as classes, their names are represented as association role names. Association role names are only displayed if they differ from the associated class name. The diagram shows the data hierarchy excluding the details of participation. The default multiplicity is 1..1.

v 3.1 5

### 2.5 ADVERSE REACTION

### Identification

Label ADVERSE REACTION

Metadata Type Data Group Identifier DG-15517

**OID** 1.2.36.1.2001.1001.101.102.15517

### **Definition**

**Definition** 

agent, including food, plants, animals, venom from animal stings or a medication at therapeutic or sub-therapeutic doses.

Definition Source NEHTA

Synonymous Reaction
Allergy
Allergic
Adverse
Event
Effect
Sensitivity

A harmful or undesirable effect associated with exposure to any substance or

Sensitivity
Intolerance
Hypersensitivity
Side Effect
Toxicity
Interaction
Drug
Food
Medication
Agent
Substance
Immune
Non-Immune

Chemical

# **Data Hierarchy**

ADVEF	ADVERSE REACTION						
001011001	Substance/Agent 1						
<b>4</b>	Absolute Contraindication	01					
T	Comment (Adverse Reaction Comment)	01					
	REACTION EVENT	0*					

		Specific	- Cubata	cos/A cont	01		
	001011001	Special	Specific Substance/Agent				
	001011001	Manifes	Manifestation				
	001011001	Reaction	Reaction Type				
	001011001	Certain	ty (Adve	rse Reaction Certainty)	01		
	T	Reaction	n Descri	ption	01		
	7 <sup>th</sup>	Onset o	of Reacti	on (Reaction Onset Date)	01		
		Duratio	n of Rea	ction	01		
		Additio	nal Reac	tion Detail (ANATOMICAL LOCATION)	0*		
			SPECII	FIC LOCATION	01		
			001011001	Name of Location (Anatomical Location Name)	01		
			001011001	Side	01		
			001011001	Numerical Identifier	01		
			001011001	Anatomical Plane	01		
			RELAT	VE LOCATION	0*		
			001011001	Identified Landmark	01		
			001011001	Aspect (Anatomical Location Aspect)	01		
				Distance From Landmark	01		
		T	Descrip	tion (Anatomical Location Description)	0*		
		T	Visual I	Markings/Orientation	0*		
		001011001	Image	Anatomical Location Image)	0*		
	T	Exposu	Exposure Description				
	7 <sup>th</sup>	Earliest	Earliest Exposure				
		Duratio	Duration of Exposure				
		ADDITI	ONAL E	XPOSURE DETAIL	0*		

			AMOUI	NT OF MEDICATION	01
			312	Quantity	01
			001011001	Dose Unit	01
			T	Quantity Description	01
		•	TIMING		01
			<b>1</b>	Frequency Range (Intervention Frequency Range)	01
			<b>1</b>	Interval Range (Intervention Interval Range)	01
			7 <sup>th</sup>	Time (Intervention Time)	0*
			001011001	Day of Week (Intervention Day of Week)	0*
			123	Day of Month (Intervention Day of Month)	0*
			7 <sup>t</sup>	Date (Intervention Date)	0*
		•	MEDIC	ATION ADMINISTRATION	01
			001011001	Route	01
			001011001	Site (Anatomical Site)	01
			T	Delivery Method (Medication Delivery Method)	01
				Dose Duration	01
			T	Intravenous Details (Intravenous Administration Details)	0*
	T	Clinica	l Manage	ment Description	01
	001011001	Multime	edia		0*
	T	Report	orting Details		
	T	Comme	nent (Adverse Reaction Event Comment)		
<b>*</b>	Reaction	ction Reported			01
	Advers	e Reacti	Adverse Reaction Report 0		

#### nehta

	Supporting Clinical Record Information					
8	INFORMATION PROVIDER	01				
8	SUBJECT	01				
46 XV 8 9 3 A	Adverse Reaction Instance Identifier	01				
•	LINK					
	Link Nature	11				
	Link Role	01				
	Link Target	11				
46 XV 8 9 7 A	Detailed Clinical Model Identifier	11				

# 2.6 Substance/Agent

### Identification

LabelSubstance/AgentMetadata TypeData ElementIdentifierDE-15521

**OID** 1.2.36.1.2001.1001.101.103.15521

### **Definition**

**Definition** Identification of a substance, agent, or a class of substance, that is considered to

be responsible for the adverse reaction.

Definition Source NEHTA
Synonymous Agent
Names Substance

**Notes**An agent can be a substance such as food, drug or an environmental allergen.

Data Type Codeable Text

Value Domain Substance/Agent Values

### **Usage**

Examples 1. Animal protein

2. Latex

3. Peanut

4. Penicillin

5. Bee venom

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	11

# 2.7 Substance/Agent Values

### Identification

Label Substance/Agent Values

Metadata Type Value Domain Identifier VD-15521

**OID** 1.2.36.1.2001.1001.101.104.15521

### **Definition**

**Definition** The set of values for the agent/substance causing the adverse reaction experienced

by the subject of care.

**Definition Source NEHTA** 

### **Value Domain**

Source	NEHTA
Permissible Values	The permissible values are the members of the following 8 reference sets.
values	From SNOMED CT-AU:
	32570211000036100  Substance foundation reference set
	From AMT:
	929360061000036106  Medicinal product reference set
	929360081000036101  Medicinal product pack reference set
	929360071000036103  Medicinal product unit of use reference set
	929360021000036102   Trade product reference set
	929360041000036105   Trade product pack reference set
	929360031000036100   Trade product unit of use reference set

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Substance/Agent	11

• 929360051000036108 |Containered trade product pack reference set|

# 2.8 Absolute Contraindication

### Identification

Label **Absolute Contraindication** 

**Metadata Type Data Element** Identifier DE-16073

OID 1.2.36.1.2001.1001.101.103.16073

### **Definition**

Definition A flag indicating that a clinician has identified a propensity for a serious reaction

upon further exposure to the substance/agent.

**Definition Source NEHTA** 

**Synonymous Names** 

**Data Type** Boolean

# **Usage**

**Conditions of** Record as "true" if the clinician assesses that exposure to, or administration of, Use

the agent should be avoided in future.

False is not a valid value for this data element.

**Conditions of Use Source** 

**NEHTA** 

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	01

# 2.9 Adverse Reaction Comment

### Identification

LabelCommentMetadata TypeData ElementIdentifierDE-15590

**OID** 1.2.36.1.2001.1001.101.103.15590

### **Definition**

**Definition** Additional narrative about the adverse reaction not captured in other fields, including

reason for flagging an absolute contraindication, instructions related to future

exposure or administration of the substance/agent.

**Definition Source NEHTA** 

Synonymous Re

Names

Reaction Note

Notes Used to provide additional narrative information in relation to the adverse reaction

such as finding site or route of administration.

Data Type Text

### **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	01

# 2.10 REACTION EVENT

### Identification

Label REACTION EVENT

Metadata Type Data Group Identifier DG-16474

**OID** 1.2.36.1.2001.1001.101.102.16474

### **Definition**

**Definition** Details about each adverse reaction event.

**Definition Source NEHTA** 

Synonymous Names

# Relationships

#### **Parents**

,	Data Type	Name	Occurrences (child within parent)
		ADVERSE REACTION	0*

#### Children

Data Type	Name	Occurrences
001011001	Specific Substance/Agent	01
001011001	Manifestation	0*
001011001	Reaction Type	01
001011001	Certainty (Adverse Reaction Certainty)	01
T	Reaction Description	01
7 <sup>th</sup>	Onset of Reaction (Reaction Onset Date)	01
	Duration of Reaction	01
	Additional Reaction Detail (ANATOMICAL LOCATION)	0*

Data Type	Name	Occurrences
T	Exposure Description	01
7th	Earliest Exposure	01
	Duration of Exposure	01
	ADDITIONAL EXPOSURE DETAIL	0*
T	Clinical Management Description	01
001011001	Multimedia	0*
T	Reporting Details	0*
T	Comment (Adverse Reaction Event Comment)	01

# 2.11 Specific Substance/Agent

### Identification

Label Specific Substance/Agent

Metadata Type Data Element Identifier DE-16349

**OID** 1.2.36.1.2001.1001.101.103.16349

### **Definition**

**Definition** Specific identification of the substance/agent considered to be responsible for the

adverse reaction event.

**Definition Source NEHTA** 

Synonymous Names

**Notes** This may include a medication trade name.

Data Type Codeable Text

Value Domain Substance/Agent Values

### **Usage**

**Examples** 

Misuse To record broad classes of substance such as "food" or "antibiotic".

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

### 2.12 Manifestation

### Identification

LabelManifestationMetadata TypeData ElementIdentifierDE-15564

**OID** 1.2.36.1.2001.1001.101.103.15564

### **Definition**

**Definition** Clinical manifestation of the adverse reaction expressed as a single word, phrase or brief description. **Definition Source NEHTA Synonymous** Reaction **Names Notes** The clinical manifestation (signs, symptoms, severity or certainty) of the adverse reaction are relevant as they contribute towards the decision as to the immediacy and extent of treatment to be provided, as determined by a healthcare provider. Given that an adverse reaction has occurred, it is important to determine the manifestations of that reaction. **Data Type** CodeableText **Clinical Manifestation Values Value Domain** 

### **Usage**

Examples
1. Itchy eyes
2. Dysphagia
3. Tinnitus
4. Nausea
5. Rash

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	0*

### 2.13 Clinical Manifestation Values

### Identification

Clinical Manifestation Values Label

**Metadata Type** Value Domain Identifier VD-15564

OID 1.2.36.1.2001.1001.101.104.15564

**External** SNOMED CT-AU Concept ID: 32570071000036102

Identifier

#### **Definition**

Definition The Clinical manifestation values reference set provides the broadest possible

terminology to support the recording of Clinical Manifestation of Adverse Reaction

in Australian eHealth implementations.

**Definition Source NEHTA** 

### Value Domain

Source SNOMED CT-AU

**Permissible** Not yet defined. Until it is defined use the Clinical finding foundation reference set **Values** 

(SNOMED CT-AU Concept ID: 32570071000036102).

Please see Appendix A, Known Issues

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Manifestation	11

# 2.14 Reaction Type

# Identification

LabelReaction TypeMetadata TypeData ElementIdentifierDE-15554

**OID** 1.2.36.1.2001.1001.101.103.15554

### **Definition**

Definition	The type of reaction, as determined by the clinician.
<b>Definition Source</b>	NEHTA
Synonymous Names	
Context	This field is used to identify the type of adverse reaction as determined by:
	<ul> <li>the signs and/or symptoms experienced by the subject of care;</li> </ul>
	information provided by a relevant individual;
	previously documented history; and/or
	a clinical assessment by a healthcare provider.
Context Source	NEHTA
Notes	Examples include Immune mediated - Types I-IV (including allergy and hypersensitivity); Non-immune mediated - including pseudoallergic reaction, side effect, intolerance, drug toxicity, drug-drug interaction, food-drug interaction, drug-disease interaction and idiosyncratic reaction.
Data Type	CodeableText
Value Domain	Not specified.
	In the absence of national standard code sets, the code sets used <b>SHALL</b> be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u> <sup>1</sup> with an appropriate object identifier (OID), and <b>SHALL</b> be publicly available.
	When national standard code sets become available, they <b>SHALL</b> be used and the non-standard code sets <b>SHALL</b> be deprecated.

# **Usage**

Examples	1. Allergy
	2. Idiosyncrasy
	3. Interactions

<sup>1</sup> http://www.hl7.org/oid/index.cfm

- 4. Intolerance / sensitivity
- 5. Pseudoallergy / anaphylactoid reaction
- 6. Side effects

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

# 2.15 Adverse Reaction Certainty

### Identification

LabelCertaintyMetadata TypeData ElementIdentifierDE-15568

**OID** 1.2.36.1.2001.1001.101.103.15568

### **Definition**

**Definition** Degree of certainty, as assessed by the clinician, that the specific substance/agent was the cause of the reaction. **Definition Source NEHTA Synonymous Names Notes** It is important to know the degree of certainty of an adverse reaction to an agent/substance as there may be instances where it is not clear whether it is the active agent or a secondary component causing the problem. For example, it may be the filler in a tablet that is the allergen rather than the active drug. Another example is where there is suspicion of a reaction that warrants recording but has not been confirmed objectively, or where a reaction has been recorded but is subsequently discounted following further observation or investigation. CodedText **Data Type Value Domain Adverse Reaction Certainty Values** 

### **Usage**

robable
Inlikely

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
<b>%</b>	REACTION EVENT	01

v 3.1 21

# 2.16 Adverse Reaction Certainty Values

### Identification

Label Adverse Reaction Certainty Values

Metadata Type Value Domain Identifier VD-15568

**OID** 1.2.36.1.2001.1001.101.104.15568

### **Definition**

**Definition** The set of values for the degree of confidence that the agent/substance has caused

the adverse reaction.

**Definition Source NEHTA** 

### **Value Domain**

Source	WHO-UMC causality assessment system.		
Permissible Values	Certain	A clinical event, including laboratory test abnormality, occurring in a plausible time relationship to agent exposure or administration, and which cannot be explained by concurrent disease or other agents or chemicals. The response to withdrawal of the agent (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.	
	Probable/Likely	A clinical event, including laboratory test abnormality, with a reasonable time relationship to agent exposure or administration, unlikely to be attributed to concurrent disease or other agents or chemicals, and which follows a clinically reasonable response on withdrawal (dechallenge) Rechallenge information is not required to fulfil this definition.	
	Possible	A clinical event, including laboratory test abnormality, with a reasonable time relationship to agent exposure or administration, but which could also be explained by concurrent disease or other agents or chemicals. Information on agent withdrawal may be lacking or unclear.	
	Unlikely	A clinical event, including laboratory test abnormality, with a temporal relationship to agent exposure or administration which makes a causal relationship improbable, and in which	

	other agents, chemicals or underlying disease provide plausible explanations.
Conditional/Unclassified	A clinical event, including laboratory test abnormality, reported as an adverse reaction, about which more data are required for a proper assessment or the additional data are under examination.
Unassessable/Unclassifiable	A reported adverse reaction which cannot be judged because information is insufficient or contradictory, and which cannot be supplemented or verified.

# Usage

Conditions of Use	The value domain options are mutually exclusive and cannot be used in conjunction with each other.
Conditions of	Amended from:
Use Source	1. [EDWA1994a]
	The use of the WHO-UMC system for standardised case causality assessment [UMC2011a]
	Note: These sources specifically relate to drug adverse events or pharmacovigilance. Amendments were made to broaden the assessment to all agents that might cause or be suspected of causing an adverse event.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Certainty (Adverse Reaction Certainty)	11

v 3.1 23

# 2.17 Reaction Description

### Identification

Label Reaction Description

Metadata Type Data Element
Identifier DE-15563

**OID** 1.2.36.1.2001.1001.101.103.15563

### **Definition**

Definition Narrative description of the reaction.

Definition Source NEHTA

Synonymous Reaction

Names

Data Type Text

# **Usage**

1. Itchy eyes2. Dysphagia

3. Tinnitus

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

# 2.18 Reaction Onset Date

### Identification

Label Onset of Reaction

Metadata Type Data Element

Identifier DE-15507

**OID** 1.2.36.1.2001.1001.101.103.15507

### **Definition**

Definition Record of the date or time (or both) of the onset of the reaction.

Definition Source NEHTA

Synonymous DateTime Started

Names

Notes The date or date and time that the specific reaction commenced.

Sometimes, the date or age at which a person reacts to an agent is a relevant to

Sometimes, the date or age at which a person reacts to an agent is a relevant to understanding a condition, or to determining appropriate treatment. Often, this will

be an approximate, self-reported age, date or datetime.

Data Type Date Time

### **Usage**

Please see DateTime in Appendix B, Specification Guide for Use for examples

and usage information on specifying a date or time (or both).

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

v 3.1 25

# 2.19 Duration of Reaction

### Identification

Label Duration of Reaction

Metadata Type Data Element
Identifier DE-16352

**OID** 1.2.36.1.2001.1001.101.103.16352

### **Definition**

**Definition** Length of duration of the reaction.

**Definition Source NEHTA** 

Synonymous Names

Data Type Duration

# **Usage**

#### **Examples**

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

### 2.20 ANATOMICAL LOCATION

#### Identification

Label Additional Reaction Detail

Metadata Type Data Group Identifier DG-16150

**OID** 1.2.36.1.2001.1001.101.102.16150

#### **Definition**

**Definition** Additional detail about the reaction, including anatomical location.

**Definition Source NEHTA** 

Synonymous Names

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	0*

#### Children

Data Type	Name	Occurrences
	SPECIFIC LOCATION	01
	RELATIVE LOCATION	0*
T	Description (Anatomical Location Description)	0*
T	Visual Markings/Orientation	0*
001011001	Image (Anatomical Location Image)	0*

### 2.21 SPECIFIC LOCATION

#### Identification

Label SPECIFIC LOCATION

Metadata Type Data Group Identifier DG-16151

**OID** 1.2.36.1.2001.1001.101.102.16151

### **Definition**

**Definition** Specific and identified anatomical location.

**Definition Source NEHTA** 

Synonymous Names

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	Additional Reaction Detail (ANATOMICAL LOCATION)	01

#### Children

Data Type	Name	Occurrences
001011001	Name of Location (Anatomical Location Name)	01
001011001	Side	01
001011001	Numerical Identifier	01
001011001	Anatomical Plane	01

### 2.22 Anatomical Location Name

#### Identification

LabelName of LocationMetadata TypeData ElementIdentifierDE-16153

**OID** 1.2.36.1.2001.1001.101.103.16153

#### **Definition**

**Definition** The name of the anatomical location.

**Definition Source NEHTA** 

Synonymous Names

**Data Type** 

CodeableText

Value Domain Body Structure Foundation Reference Set

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	SPECIFIC LOCATION	01

# **2.23 Body Structure Foundation Reference Set**

#### Identification

Label Body Structure Foundation Reference Set

Metadata Type Value Domain VD-16152

**OID** 1.2.36.1.2001.1001.101.104.16152

External SNOMED CT-AU Concept Id: 32570061000036105

Identifier

#### **Definition**

**Definition** The set of values for named anatomical locations.

**Definition Source NEHTA** 

#### **Value Domain**

Source SNOMED CT-AU

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Name of Location (Anatomical Location Name)	11

### **2.24 Side**

### Identification

Label Side

Metadata Type Data Element Identifier DE-16336

**OID** 1.2.36.1.2001.1001.101.103.16336

#### **Definition**

**Definition** The laterality of the anatomical location.

Definition Source NEHTA
Synonymous Laterality

Names

Data Type CodedText

Value Domain Laterality Reference Set

### **Usage**

Examples 1. Right

2. Left

3. Bilateral

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	SPECIFIC LOCATION	01

## 2.25 Laterality Reference Set

#### Identification

Laterality Reference Set

Metadata Type Value Domain Identifier VD-16312

**OID** 1.2.36.1.2001.1001.101.104.16312

External SNOMED CT-AU Concept Id: 32570611000036103

Identifier

#### **Definition**

**Definition** The set of values for identifying the laterality of an anatomical location.

**Definition Source NEHTA** 

#### **Value Domain**

Source SNOMED CT-AU

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Side	11

### 2.26 Numerical Identifier

#### Identification

**Numerical Identifier** Label

**Metadata Type Data Element** Identifier DE-16338

OID 1.2.36.1.2001.1001.101.103.16338

#### **Definition**

**Definition** An ordinal number that identifies the specific anatomical site from multiple sites.

**Definition Source NEHTA** 

**Synonymous Names** 

CodedText

**Data Type Value Domain** Not specified.

> In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> procedure<sup>2</sup> with an appropriate object identifier (OID), and **SHALL** be publicly available.

When national standard code sets become available, they SHALL be used and the non-standard code sets **SHALL** be deprecated.

### **Usage**

**Conditions of** This **SHALL** be an ordinal number between first and eighteenth. Use

**Conditions of Use Source** 

**NEHTA** 

**Examples** 1. First, as in 'first rib'.

2. Second, as in 'second toe'.

3. Third, as in 'third lumbar vertebra'.

<sup>&</sup>lt;sup>2</sup> http://www.hl7.org/oid/index.cfm

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	SPECIFIC LOCATION	01

### 2.27 Anatomical Plane

#### Identification

**Anatomical Plane** Label Metadata Type **Data Element** Identifier DE-16340

OID 1.2.36.1.2001.1001.101.103.16340

#### **Definition**

**Definition** Line describing the position of a vertical anatomical plane in the body.

**Definition Source NEHTA** 

**Synonymous Names** 

CodedText

**Data Type Value Domain** Not specified.

> In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u><sup>3</sup> with an appropriate object identifier (OID), and **SHALL** be publicly available.

When national standard code sets become available, they SHALL be used and the non-standard code sets **SHALL** be deprecated.

### **Usage**

**Examples** 1. Midline

2. Midclavicular

3. Midaxillary

4. Midscapular

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	SPECIFIC LOCATION	01

<sup>3</sup> http://www.hl7.org/oid/index.cfm

### 2.28 RELATIVE LOCATION

#### Identification

Label RELATIVE LOCATION

Metadata Type Data Group Identifier DG-16341

**OID** 1.2.36.1.2001.1001.101.102.16341

#### **Definition**

**Definition** Qualifier(s) to identify a non-specific location.

**Definition Source NEHTA** 

Synonymous Names

**Notes** An example is: 5cm (distance) inferior (aspect) to the tibial tuberosity (landmark).

There may be more than one relative location required to provide a cross reference.

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	Additional Reaction Detail (ANATOMICAL LOCATION)	0*

#### Children

Data Type	Name	Occurrences
001011001	Identified Landmark	01
001011001	Aspect (Anatomical Location Aspect)	01
	Distance From Landmark	01

### 2.29 Identified Landmark

#### Identification

Label Identified Landmark

Metadata Type Data Element Identifier DE-16343

**OID** 1.2.36.1.2001.1001.101.103.16343

#### **Definition**

**Definition** Identified anatomical landmark from which to specify the relative anatomical

location.

**Definition Source NEHTA** 

Synonymous Names

Data Type CodeableText Value Domain Not specified.

In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u><sup>4</sup> with an appropriate object identifier (OID), and **SHALL** be publicly

available.

When national standard code sets become available, they **SHALL** be used and

the non-standard code sets SHALL be deprecated.

### **Usage**

**Examples** 

### Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	RELATIVE LOCATION	01

<sup>4</sup> http://www.hl7.org/oid/index.cfm

### 2.30 Anatomical Location Aspect

#### Identification

Label Aspect

Metadata Type Data Element
Identifier DE-16345

**OID** 1.2.36.1.2001.1001.101.103.16345

#### **Definition**

**Definition** Qualifier to identify which direction the anatomical location is in relation to the

identified landmark.

**Definition Source NEHTA** 

Synonymous Names

Data Type CodedText

Value Domain Not specified.

In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u><sup>5</sup> with an appropriate object identifier (OID), and **SHALL** be publicly available.

When national standard code sets become available, they **SHALL** be used and the non-standard code sets **SHALL** be deprecated.

#### **Usage**

Medial to: Relative location medial to the landmark.

2. Lateral to: Relative location lateral to the landmark.

3. Superior to: Relative location superior to the landmark.

4. Inferior to: Relative location inferior to the landmark.

5. Anterior to: Relative location anterior to the landmark.

6. Posterior to: Relative location posterior to the landmark.

7. Below: Relative location below the landmark.

8. Above: Relative location above the landmark.

9. Inferolateral to: Relative location inferior and lateral to the landmark.

10. Superolateral to: Relative location superior and lateral to the landmark.

11. Inferomedial to: Relative location inferior and medial to the landmark.

<sup>&</sup>lt;sup>5</sup> http://www.hl7.org/oid/index.cfm

12 Superomedial to: Relative location superior and medial to the landmark.

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	RELATIVE LOCATION	01

### 2.31 Distance From Landmark

#### Identification

Label Distance From Landmark

Metadata Type Data Element Identifier DE-16346

**OID** 1.2.36.1.2001.1001.101.103.16346

Quantity

#### **Definition**

Definition Distance of location from the identified landmark.

Definition Source NEHTA

Synonymous Names

**Usage** 

**Data Type** 

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	RELATIVE LOCATION	01

## 2.32 Anatomical Location Description

#### Identification

LabelDescriptionMetadata TypeData ElementIdentifierDE-16319

**OID** 1.2.36.1.2001.1001.101.103.16319

#### **Definition**

Definition Description of the anatomical location.

Definition Source NEHTA

Synonymous Names

Data Type Text

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	Additional Reaction Detail (ANATOMICAL LOCATION)	0*

## 2.33 Visual Markings/Orientation

#### Identification

Label Visual Markings/Orientation

Metadata Type Data Element Identifier DE-16407

**OID** 1.2.36.1.2001.1001.101.103.16407

#### **Definition**

Definition	Description of any visual markings used to orientate the viewer.
<b>Definition Source</b>	NEHTA
Synonymous Names	
Data Type	Text

### **Usage**

Examples 1. External reference points

2. Special sutures

3. Ink markings

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	Additional Reaction Detail (ANATOMICAL LOCATION)	0*

## 2.34 Anatomical Location Image

#### Identification

Label Image

Metadata Type Data Element Identifier DE-16199

**OID** 1.2.36.1.2001.1001.101.103.16199

#### **Definition**

**Definition** An image or images used to identify a location.

**Definition Source NEHTA** 

Synonymous Names

Context This element is intended to be an image, e.g. a photo of the anatomical site such

as a wound on the leg.

Context Source NEHTA

Data Type EncapsulatedData

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	Additional Reaction Detail (ANATOMICAL LOCATION)	0*

## 2.35 Exposure Description

### Identification

**Label** Exposure Description

Text

Metadata Type Data Element
Identifier DE-16477

**OID** 1.2.36.1.2001.1001.101.103.16477

#### **Definition**

Definition Description about exposure to the substance/agent.

Definition Source NEHTA

Synonymous Names

**Usage** 

**Data Type** 

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

## 2.36 Earliest Exposure

#### Identification

Label Earliest Exposure
Metadata Type Data Element

Identifier DE-16372

**OID** 1.2.36.1.2001.1001.101.103.16372

#### **Definition**

**Definition** Record of the date or time (or both) of the earliest or initial exposure to the

substance/agent.

**Definition Source NEHTA** 

Synonymous Names

Data Type Date Time

### **Usage**

**Examples** Please see DateTime in Appendix B, Specification Guide for Use for examples

and usage information on specifying a date or time (or both).

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

## 2.37 Duration of Exposure

#### Identification

Label Duration of Exposure

Metadata Type Data Element Identifier DE-16373

**OID** 1.2.36.1.2001.1001.101.103.16373

#### **Definition**

**Definition** Length of duration of exposure.

**Definition Source NEHTA** 

Synonymous Names

Notes Used to describe the length of exposure to a substance/agent triggering a specific

reaction event.

Data Type Duration

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

### 2.38 ADDITIONAL EXPOSURE DETAIL

#### Identification

Label ADDITIONAL EXPOSURE DETAIL

Metadata Type Choice Identifier C-16478

**OID** 1.2.36.1.2001.1001.101.105.16478

#### **Definition**

Definition Additional detail about exposure/s for this reaction event, including structured medication amount information.

Definition Source NEHTA

Synonymous Names

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	0*

#### Children

Data Type	Name	Occurrences
	AMOUNT OF MEDICATION	01
	TIMING	01
	MEDICATION ADMINISTRATION	01

### 2.39 AMOUNT OF MEDICATION

#### Identification

Label AMOUNT OF MEDICATION

Metadata Type Data Group Identifier DG-16423

**OID** 1.2.36.1.2001.1001.101.102.16423

#### **Definition**

**Definition** Additional detail about exposure/s for this reaction event, including structured

medication amount information.

**Definition Source NEHTA** 

Synonymous Names

Scope Used to record additional details of exposure to a substance/agent that triggered

the adverse reaction event.

Scope Source NEHTA

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADDITIONAL EXPOSURE DETAIL	01

#### Children

Data Type	Name	Occurrences
312	Quantity	01
001011001	Dose Unit	01
T	Quantity Description	01

## 2.40 Quantity

### Identification

Label Quantity

Metadata Type Data Element Identifier DE-10145

**OID** 1.2.36.1.2001.1001.101.103.10145

#### **Definition**

**Definition** The quantity, number or proportion.

**Definition Source NEHTA** 

Synonymous Names

**Notes** The number of doses or physical amount of the therapeutic good.

Data Type Real Quantity

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	AMOUNT OF MEDICATION	01

### 2.41 Dose Unit

#### Identification

LabelDose UnitMetadata TypeData ElementIdentifierDE-16524

**OID** 1.2.36.1.2001.1001.101.103.16524

#### **Definition**

**Definition** The dose unit of this amount.

**Definition Source NEHTA** 

Synonymous Names

Data Type CodedText

Value Domain Dose Unit Reference Set

### **Usage**

Examples 1. Tablets

2. Capsules

3. Sachets

4. mg

5. mL

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	AMOUNT OF MEDICATION	01

### 2.42 Dose Unit Reference Set

#### Identification

Label Dose Unit Reference Set

Metadata Type Value Domain VD-16523

**OID** 1.2.36.1.2001.1001.101.104.16523

External SNOMED CT-AU Concept Id: 32570641000036102

Identifier

#### **Definition**

**Definition** The set of values for dose unit.

**Definition Source NEHTA** 

#### **Value Domain**

Source SNOMED CT-AU

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Dose Unit	11

## 2.43 Quantity Description

### Identification

Label Quantity Description

Metadata Type Data Element
Identifier DE-16525

**OID** 1.2.36.1.2001.1001.101.103.16525

#### **Definition**

**Definition** Free text description of the amount which may consist of the quantity and dose

unit.

**Definition Source NEHTA** 

Synonymous Names

Data Type Text

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	AMOUNT OF MEDICATION	01

### **2.44 TIMING**

#### Identification

LabelTIMINGMetadata TypeData GroupIdentifierDG-16431

**OID** 1.2.36.1.2001.1001.101.102.16431

#### **Definition**

Definition
Definition Source
Definition Source
Synonymous
Names
Notes
It is for recording timing of exposure to the substance or agent, including medication or vaccine.

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADDITIONAL EXPOSURE DETAIL	01

#### Children

Data Type	Name	Occurrences
<u></u>	Frequency Range (Intervention Frequency Range)	01
<b>1</b>	Interval Range (Intervention Interval Range)	01
7 <sup>th</sup>	Time (Intervention Time)	0*
001011001	Day of Week (Intervention Day of Week)	0*
123	Day of Month (Intervention Day of Month)	0*
7 ***	Date (Intervention Date)	0*

## 2.45 Intervention Frequency Range

#### Identification

LabelFrequency RangeMetadata TypeData ElementIdentifierDE-16547

**OID** 1.2.36.1.2001.1001.101.103.16547

#### **Definition**

**Definition** The frequency as number of times per time period that the intervention is to take

place.

**Definition Source NEHTA** 

Synonymous Names

**Notes** Includes details of variable upper and lower frequency e.g. 3-4 times a day.

Data Type QuantityRange

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	TIMING	01

## 2.46 Intervention Interval Range

#### Identification

LabelInterval RangeMetadata TypeData ElementIdentifierDE-16548

**OID** 1.2.36.1.2001.1001.101.103.16548

#### **Definition**

Definition The length of time between doses or interventions.

Definition Source NEHTA

Synonymous Names

Notes 8 Hourly is PT8H, monthly is P1M, every hour and a half is PT1H30M.

Includes details of variable upper and lower intervals e.g. every 2-3 hours.

Data Type QuantityRange

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	TIMING	01

### 2.47 Intervention Time

#### Identification

Label Time

**Metadata Type Data Element** Identifier DE-16549

OID 1.2.36.1.2001.1001.101.103.16549

#### **Definition**

**Definition** Specific time(s) during the day when the intervention should be applied.

**Definition Source NEHTA** 

**Synonymous Names** 

**Data Type** DateTime

### **Usage**

**Conditions of** This **SHALL NOT** contain a date component.

Use

**Conditions of** 

**Use Source** 

**NEHTA** 

Please see DateTime in Appendix B, Specification Guide for Use for examples **Examples** 

and usage information on specifying a time.

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	TIMING	0*

### 2.48 Intervention Day of Week

#### Identification

LabelDay of WeekMetadata TypeData ElementIdentifierDE-16551

**OID** 1.2.36.1.2001.1001.101.103.16551

#### **Definition**

**Definition** The specific and repeating day(s) of the week.

**Definition Source NEHTA** 

Synonymous Names

Data Type CodedText
Value Domain Not specified.

In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the  $\underline{\textit{HL7 code set registration}}$  with an appropriate object identifier (OID), and **SHALL** be publicly

available.

When national standard code sets become available, they **SHALL** be used and the non-standard code sets **SHALL** be deprecated.

### **Usage**

Examples 1. Monday

2. Wednesday

3. Friday

4. Sunday

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	TIMING	0*

<sup>&</sup>lt;sup>6</sup> http://www.hl7.org/oid/index.cfm

## 2.49 Intervention Day of Month

#### Identification

LabelDay of MonthMetadata TypeData ElementIdentifierDE-16552

**OID** 1.2.36.1.2001.1001.101.103.16552

#### **Definition**

 Definition
 The specific and repeating day(s) of the month.

 Definition Source
 NEHTA

 Synonymous Names
 If it is required to give a dose on the 2nd day of each month, then the value is 2.

 Data Type
 Integer

### **Usage**

**Examples** 

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	TIMING	0*

### 2.50 Intervention Date

#### Identification

Label Date

Metadata Type Data Element Identifier DE-16553

**OID** 1.2.36.1.2001.1001.101.103.16553

#### **Definition**

Definition Actual dates.

Definition Source NEHTA

Synonymous Names

Data Type DateTime

### **Usage**

**Examples** Please see DateTime in Appendix B, Specification Guide for Use for examples

and usage information on specifying a date or time (or both).

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	TIMING	0*

#### 2.51 MEDICATION ADMINISTRATION

#### Identification

Label MEDICATION ADMINISTRATION

Metadata Type Data Group
Identifier DG-10108

**OID** 1.2.36.1.2001.1001.101.102.10108

#### **Definition**

 Definition
 Details about the administration of the medicine, vaccine or other therapeutic good.

 Definition Source
 NEHTA

 Synonymous Names
 Used to describe the exposure mechanism to the substance or agent. This includes the route, anatomical site, delivery methods of medications.

 Scope Source
 NEHTA

Usage

**Conditions of Use**This data group is repeated for every instance of medication administration being recorded.

Conditions of Use Source

NEHTA

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADDITIONAL EXPOSURE DETAIL	01

#### Children

Data Type	Name	Occurrences
001011001	Route	01
001011001	Site (Anatomical Site)	01
T	Delivery Method (Medication Delivery Method)	01

Data Type	Name	Occurrences
	Dose Duration	01
T	Intravenous Details (Intravenous Administration Details)	0*

### **2.52 Route**

#### Identification

Label Route

Metadata Type Data Element Identifier DE-10147

**OID** 1.2.36.1.2001.1001.101.103.10147

#### **Definition**

**Definition** The route by which the medication is administered.

**Definition Source NEHTA** 

Synonymous Names

Route of Administration

**Notes** It is used to describe the path or channel by which the substance/agent is

introduced or gains access into a patient's body. This includes the route for which

medication is administered.

Data Type Codeable Text

Value Domain Route of Administration Reference Set

### **Usage**

Conditions of Use "Unknown" only for retrospective data collection.
Use

Conditions of Use Source

NEHTA

Examples 1. Oral

2. Subcutaneous injection

3. Epidural

4. Rectal

5. Otic

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	MEDICATION ADMINISTRATION	01

# **2.53 Route of Administration Reference Set**

### Identification

Label Route of Administration Reference Set

Metadata Type Value Domain Identifier VD-10147

**OID** 1.2.36.1.2001.1001.101.104.10147

External SNOMED CT-AU Concept Id: 32570601000036100

Identifier

### **Definition**

**Definition** A list of all possible routes of administration of medication.

**Definition Source NEHTA** 

**Notes** Set of allowable values to describe the way through which a medication is

administered to/by the subject of care.

#### **Value Domain**

Source SNOMED CT-AU

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Route	11

## 2.54 Anatomical Site

## Identification

Label Site

Metadata Type Data Element Identifier DE-10156

**OID** 1.2.36.1.2001.1001.101.103.10156

#### **Definition**

**Definition** A description of the site of administration.

**Definition Source NEHTA** 

Synonymous Names

Notes Location on or in the body of the subject of care where the substance/agent entered

the body or therapeutic good was administered.

Data Type Codeable Text

Value Domain Body Structure Foundation Reference Set

## **Usage**

Examples 1. Left thigh

2. Upper arm

3. Entire left renal artery

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	MEDICATION ADMINISTRATION	01

# 2.55 Body Structure Foundation Reference Set

### Identification

Label Body Structure Foundation Reference Set

Metadata Type Value Domain VD-16152

**OID** 1.2.36.1.2001.1001.101.104.16152

External SNOMED CT-AU Concept Id: 32570061000036105

Identifier

### **Definition**

**Definition** The set of values for named anatomical locations.

**Definition Source NEHTA** 

#### **Value Domain**

Source SNOMED CT-AU

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Site (Anatomical Site)	11

# 2.56 Medication Delivery Method

## Identification

LabelDelivery MethodMetadata TypeData ElementIdentifierDE-16470

**OID** 1.2.36.1.2001.1001.101.103.16470

## **Definition**

Definition	The method of delivery if this should be specified.
<b>Definition Source</b>	NEHTA
Synonymous Names	
Data Type	Text

## **Usage**

Examples1. Delivery via nebuliser or spacer.2. Delivery via syringe pump.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	MEDICATION ADMINISTRATION	01

## 2.57 Dose Duration

## Identification

LabelDose DurationMetadata TypeData ElementIdentifierDE-16471

**OID** 1.2.36.1.2001.1001.101.103.16471

#### **Definition**

Definition The length of time over which to administer each dose.

Definition Source NEHTA

Synonymous Names

Data Type Duration

## **Usage**

Examples 1. An intravenous injection may be administered over a period of 5 minutes.

# Relationships

#### **Parents**

Data Typ	Name	Occurrences (child within parent)
	MEDICATION ADMINISTRATION	01

## 2.58 Intravenous Administration Details

#### Identification

Label Intravenous Details

Metadata Type Data Element
Identifier DE-16634

**OID** 1.2.36.1.2001.1001.101.105.16634

#### **Definition**

**Definition** Details of intravenous administration.

**Definition Source NEHTA** 

Synonymous Names

Notes This free text data element is currently a placeholder for further structured data

that is as yet undefined. See Appendix A, Known Issues for further information.

Data Type Text

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	MEDICATION ADMINISTRATION	0*

# 2.59 Clinical Management Description

## Identification

Label Clinical Management Description

Metadata Type Data Element Identifier DE-16482

**OID** 1.2.36.1.2001.1001.101.103.16482

#### **Definition**

Definition Description about the clinical management provided.

Definition Source NEHTA

Synonymous
Names

Data Type Text

## **Usage**

Conditions of Used to describe details about clinical management provided to manage or treat the adverse reaction.

Conditions of Use Source

Examples

Used to describe details about clinical management provided to manage or treat the adverse reaction.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

## 2.60 Multimedia

## Identification

LabelMultimediaMetadata TypeData ElementIdentifierDE-16376

**OID** 1.2.36.1.2001.1001.101.103.16376

#### **Definition**

 Definition
 Inclusion of any multimedia file to support the recording of the reaction event.

 Definition Source
 NEHTA

 Synonymous Names
 An example is a photo of a rash or presentation with angioneurotic oedema.

 Data Type
 EncapsulatedData

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	0*

# 2.61 Reporting Details

## Identification

LabelReporting DetailsMetadata TypeData Element

Identifier DE-16631

**OID** 1.2.36.1.2001.1001.101.105.16631

#### **Definition**

**Definition** Further details required for reporting to regulatory bodies.

**Definition Source NEHTA** 

Synonymous Names

Notes This free text data element is currently a placeholder for further structured data

that is as yet undefined. See Appendix A, Known Issues for further information.

Data Type Text

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	0*

## 2.62 Adverse Reaction Event Comment

## Identification

LabelCommentMetadata TypeData ElementIdentifierDE-16483

**OID** 1.2.36.1.2001.1001.101.103.16483

#### **Definition**

Definition Further comment about the reaction event.

Definition Source NEHTA

Synonymous Names

Data Type Text

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	REACTION EVENT	01

# 2.63 Reaction Reported

## Identification

Label Reaction Reported

Metadata Type Data Element Identifier DE-16379

**OID** 1.2.36.1.2001.1001.101.103.16379

#### **Definition**

**Definition** Was the adverse reaction reported to a regulatory body?

**Definition Source NEHTA** 

Synonymous Names

Data Type Boolean

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	01

# 2.64 Adverse Reaction Report

## Identification

Label Adverse Reaction Report

Metadata Type Data Element Identifier DE-16484

**OID** 1.2.36.1.2001.1001.101.103.16484

#### **Definition**

**Definition** Link to an adverse reaction report sent to a regulatory body.

**Definition Source NEHTA** 

Synonymous Names

Data Type Link

## **Usage**

#### **Examples**

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	0*

# 2.65 Supporting Clinical Record Information

### Identification

Label Supporting Clinical Record Information

Metadata Type Data Element
Identifier DE-16485

**OID** 1.2.36.1.2001.1001.101.103.16485

## **Definition**

Definition
Link to further information about the presentation and findings that exist elsewhere in the health record.

Definition Source
NEHTA
Synonymous
Names
Notes
Examples of further information are presenting symptoms, examination findings, diagnosis.

Data Type
Link

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	01

## 2.66 INFORMATION PROVIDER

#### Identification

Label INFORMATION PROVIDER

Metadata Type Data Group Identifier DG-10296

**OID** 1.2.36.1.2001.1001.101.102.10296

#### **Definition**

**Definition** Details pertinent to the identification of the source of the adverse reaction

information.

**Definition Source NEHTA** 

Synonymous Names

Notes This does not have to be a person and, in particular, does not have to be a

healthcare provider. Types of sources include:

· the subject of care;

· a subject of care agent, e.g. parent, guardian;

· the clinician; and

· a device or software.

## **Usage**

#### Conditions of Use

This **SHALL NOT** be used unless the provider of the information is not the *Composer/Author* of the enclosing Structured Document.

This is a reuse of the *PARTICIPATION* data group, which is described in Participation Data Specification [NEHT2011v].

The following constraints are additional to those specified in Participation Data Specification [NEHT2011v]. Constraints are explained in Appendix B, Specification Guide for Use.

- Participation Type **SHALL** have an implementation-specific value equivalent to "Information Provider".
- PERSON OR ORGANISATION OR DEVICE SHALL be instantiated as a PERSON or as a DEVICE.

Conditions of Use Source **NEHTA** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	01

## **2.67 SUBJECT**

## Identification

LabelSUBJECTMetadata TypeData GroupIdentifierDG-10296

**OID** 1.2.36.1.2001.1001.101.102.10296

## **Definition**

Definition	The individual about whom the adverse reaction information is being recorded.
<b>Definition Source</b>	NEHTA
Synonymous Names	
Scope	Generally only used when the recorder needs to make it explicit. Otherwise, the subject of the enclosing Structured Document is assumed.
Scope Source	NEHTA

## **Usage**

Conditions of Use	This <b>SHALL NOT</b> be used unless the subject of the information is not the <i>Subje</i> of Care of the enclosing Structured Document.		
	This is a reuse of the <i>PARTICIPATION</i> data group, which is described in Participation Data Specification [NEHT2011v].		
	The following constraints are additional to those specified in Participation Data Specification [NEHT2011v]. Constraints are explained in Appendix B, Specification Guide for Use.		
	<ul> <li>Participation Type SHALL have an implementation-specific value equivalent to "Subject".</li> </ul>		
	<ul> <li>PERSON OR ORGANISATION OR DEVICE SHALL be instantiated as a PERSON.</li> </ul>		
Conditions of Use Source	NEHTA		

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	01

# 2.68 Adverse Reaction Instance Identifier

#### Identification

Label Adverse Reaction Instance Identifier

Metadata Type Data Element
Identifier DE-16697

**OID** 1.2.36.1.2001.1001.101.103.16697

## **Definition**

 Definition
 A globally unique identifier for each instance of an Adverse Reaction evaluation.

 Definition Source
 NEHTA

 Synonymous Names
 Uniqueldentifier

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	01

## **2.69 LINK**

## Identification

Label LINK

Metadata Type Data Group Identifier DG-16692

**OID** 1.2.36.1.2001.1001.101.102.16692

## **Definition**

**Definition** A link to an instance of another Detailed Clinical Model (DCM) or a document

containing an instance of another DCM.

**Definition Source NEHTA** 

Synonymous Names

Notes Links may be to structures inside the enclosing document or inside other

documents.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	ADVERSE REACTION	0*

#### Children

Data Type	Name	Occurrences
001011001	Link Nature	11
001011001	Link Role	01
457	Link Target	11

## 2.70 Link Nature

#### Identification

LabelLink NatureMetadata TypeData ElementIdentifierDE-16698

**OID** 1.2.36.1.2001.1001.101.103.16698

#### **Definition**

**Definition** The general semantic category of the relationship between this instance of this

DCM, i.e. the source, and the target DCM instance or target document.

**Definition Source NEHTA** 

Synonymous Names

**Notes**This is one of two attributes which together communicate the semantics of the

relationship between the source and target DCMs or document. This attribute is intended to be a coarse-grained category that can be used to enable interoperability

between sender and receiver.

Data Type CodedText

Value Domain Link Nature Values

## **Usage**

Examples 1. is related to

2. is confirmed by or authorised by

3. is related to the same problem or health issue

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	LINK	11

## 2.71 Link Nature Values

## Identification

Label Link Nature Values

Metadata Type Value Domain

Identifier VD-16698

**OID** 1.2.36.1.2001.1001.101.104.16698

#### **Definition**

**Definition** The set of values for the general semantic category of the relationship between

this instance of this DCM, i.e. the source, and the target DCM instance or target

document.

**Definition Source NEHTA** 

#### Value Domain

Source ISO 13606-3:2009

Permissible Values

The permissible values are those specified in Termlist LINK\_NATURE in ISO 13606-3:2009 Health informatics - Electronic health record communication - Part 3: Reference archetypes and term lists [ISO2009a]. They are listed here.

LINK-A0, is related to

A generic category for any Link, the details of which will be given by the value of Link Role.

LINK-B0, is confirmed by or authorised by

The target link contains [an instance of a DCM or document] that acts as the legal or clinical basis for the activity documented in the source [DCM instance], or is a declaration of intent to provide (or not to provide) requested care. This Link is to be used to connect two [DCM instances or DCM and document], as opposed to the inclusion of a corroborating or authorising participant as an identified party within a single [DCM instance or document].

LINK-C0, is related to the same problem or health issue

The target [instance of a DCM or document] documents health or health care that pertains to the same clinical situation as the source [DCM instance]. One of the two might be defining a problem for which the other is a manifestation, or the relationship might for example be cause and effect, stages in an evolving clinical history, a different interpretation of an observation, a clinical indication or contraindication.

LINK-D0, is related to the same care plan, act or episode

The source and the target [instances of DCM or documents] are each documenting parts of the same care plan, act or episode. One of the

	two might be defining the same care plan, act or episode, or both might be related milestones.
LINK-E0, is a related documentation	The target [instance of a DCM or document] is an alternative documentary form of the source [DCM instance], such as re-expression of the same clinical information or additional supplementary explanatory information.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Link Nature	11

## 2.72 Link Role

#### Identification

LabelLink RoleMetadata TypeData ElementIdentifierDE-16699

**OID** 1.2.36.1.2001.1001.101.103.16699

#### **Definition**

**Definition**The detailed semantic description of the relationship between this instance of this DCM, i.e. the source, and the target DCM instance or target document.

**Definition Source NEHTA** 

Synonymous Names

**Notes**This is one of two attributes which together communicate the semantics of the

relationship between the source and target DCMs. This attribute provides for a specific description of the actual role played by the target in relation to the source. This attribute may be populated from any suitable terminology, and therefore might support human readership better than interoperable automated processing.

Data TypeCodeableTextValue DomainLink Role Values

## **Usage**

Examples 1. unspecified link

2. suggests

3. endorses

4. evidence for

5. outcome

6. is documented by

7. excerpts

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	LINK	01

## 2.73 Link Role Values

## Identification

LabelLink Role ValuesMetadata TypeValue DomainIdentifierVD-16699

**OID** 1.2.36.1.2001.1001.101.104.16699

## **Definition**

**Definition** The set of values for the detailed semantic description of the relationship between

this instance of this DCM, i.e. the source, and the target DCM instance or target

document.

**Definition Source NEHTA** 

**Context** These values are used within the context of values from *Link Role*. They provide

greater specificity and may be selected more for human readership than for

interoperable automated processing.

Context Source NEHTA

#### **Value Domain**

Source	ISO 13606-3:2009			
Permissible	Values <b>SHOULD</b> be from Termlist LINK_ROLE in ISO 13606-3:2009 [ISO2009a].			
Values	Values MAY be from any suitable terminology.			
	Some values from Termlist LINK_ROLE in ISO 13606-3:20 - Electronic health record communication - Part 3: Reference lists [ISO2009a] are:			
	LINK-A1, unspecified link	The term is used when no semantic information is available for this Link in the EHR system from which the EXTRACT has been created.		
	LINK-A2, suggests	The interpretation expressed in the target component is a possible cause or outcome of the findings documented in the source component.		
	LINK-B1, endorses	The interpretation expressed in the source component provides confirmatory evidence or a confirmatory opinion of the interpretation expressed in the target component.		
	LINK-C3, evidence for	The observation or interpretation documented in the source component provides confirmatory evidence of the interpretation expressed in the target component.		
	LINK-D1, outcome	The clinical situation documented in the target component is the direct outcome of the situation documented in the source component.		

LINK-E1, documented by	A clinical situation documented in the source component is more formally documented in the target component.
LINK-E4, excerpts	The source component is an extract (copy) of part or all of the information contained within the target component.

## **Usage**

Conditions of Use	Each of the link terms in LINK_ROLE from ISO 13606-3:2009 is a sub-category of a corresponding term in <i>Link Nature Values</i> , where that correspondence is indicated by the first letter after the code string "LINK-" e.g. the term LINK-A1 is a subcategory of term LINK-A0. If a term in this list is used for the <i>Link Role</i> data element, the appropriate corresponding value <b>SHALL</b> be used from <i>Link Nature Values</i> .
Conditions of Use Source	ISO 13606-3:2009

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Link Role	11

# 2.74 Link Target

## Identification

LabelLink TargetMetadata TypeData ElementIdentifierDE-16700

**OID** 1.2.36.1.2001.1001.101.103.16700

#### **Definition**

**Definition** The logical "to" object in the link relation, as per the linguistic sense of the *Link* 

Nature data element (and, if present, the Link Role data element).

**Definition Source NEHTA** 

Synonymous Names

Data Type Link

UniqueIdentifier

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	LINK	11

## 2.75 Detailed Clinical Model Identifier

## Identification

Label Detailed Clinical Model Identifier

Metadata Type Data Element Identifier DE-16693

**OID** 1.2.36.1.2001.1001.101.103.16693

#### **Definition**

**Definition** The NEHTA OID for the *Adverse Reaction* concept represented by this DCM.

**Definition Source NEHTA** 

Synonymous Names

Data Type UniqueIdentifier

## **Usage**

**Examples** 

**Default Value** 1.2.36.1.2001.1001.101.102.15517

Default Value Conditions of

The value of this item is fixed and **SHALL** be the default value.

# Relationships

#### **Parents**

Use

Data Type	Name	Occurrences (child within parent)
•	ADVERSE REACTION	11

# 3 Exclusion Statement - Adverse Reactions Detailed Clinical Model

This chapter describes version 1.2 of the Exclusion Statement - Adverse Reactions Detailed Clinical Model.


## 3.1 Purpose

To positively record the absence or exclusion of any adverse reactions within the health record.

## 3.2 Use

Use to record the positive exclusion or absence of adverse reactions within the health record. This DCM avoids the need to use terminology to express negation about any item within the health record. It is important to note that the Exclusion Statement information is time-specific. Its validity may not extend beyond the point in time when the information is recorded. The patient should always be asked to verify previous statements on adverse reaction to a substance.

# 3.3 UML Class Diagram



The figure represents the data hierarchy of the Detailed Clinical Model as a UML 2.0 class diagram. The diagram displays data groups and data elements, together with their names, data types and multiplicities. Data elements are displayed as attributes. Data groups are displayed as classes, their names are represented as association role names. Association role names are only displayed if they differ from the associated class name. The diagram shows the data hierarchy excluding the details of participation. The default multiplicity is 1..1.

# 3.4 EXCLUSION STATEMENT - ADVERSE REACTIONS

#### Identification

Label EXCLUSION STATEMENT - ADVERSE REACTIONS

Metadata Type Data Group Identifier DG-16137

**OID** 1.2.36.1.2001.1001.101.102.16137

## **Definition**

**Definition** Statements about adverse reactions that need to be positively recorded as absent

or excluded.

**Definition Source** openEHR Foundation

Scope To positively record the absence or exclusion of any adverse reactions within the

health record.

Scope Source openEHR Foundation

## **Data Hierarchy**

EXCLUSION STATEMENT - ADVERSE REACTIONS				
001011001	Global Statement	0*		
001011001	No Known Adverse Reaction to	01		
001011001	No Known Allergic Reaction to	01		
001011001	No Known Hypersensitivity Reaction to	01		
001011001	No Known Intolerance to	01		
8	INFORMATION PROVIDER	01		
8	SUBJECT	01		
46 X 89 3A	Exclusion Statement - Adverse Reactions Instance Identifier	01		
	LINK	0*		
	Link Nature	11		

	001011001	Link Role	01
	46 33	Link Target	11
46 XX	Detaile	d Clinical Model Identifier	11

## 3.5 Global Statement

#### Identification

LabelGlobal StatementMetadata TypeData ElementIdentifierDE-16302

**OID** 1.2.36.1.2001.1001.101.103.16302

Global Statement Values

#### **Definition**

Definition Source openEHR Foundation

Synonymous Names

Context This can be used to capture any information that is needed to be explicitly recorded as being absent or excluded within the record.

Context Source openEHR Foundation

Data Type CodedText

## **Usage**

**Value Domain** 

Conditions of Use Captures any information that is needed to be explicitly recorded as being absent or excluded within the record.

Conditions of Use Source

Examples

Captures any information that is needed to be explicitly recorded as being absent or excluded within the record.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	0*

## 3.6 Global Statement Values

## Identification

Label Global Statement Values

Metadata Type Value Domain Identifier VD-16299

**OID** 1.2.36.1.2001.1001.101.104.16299

## **Definition**

**Definition** The set of values for the global statements about the exclusion.

**Definition Source** openEHR Foundation

#### **Value Domain**

Source	NEHTA	
Permissible Values	Not asked	No information about adverse reactions to any substance is available because the patient was not asked or not able to be asked.
	None known	No information about adverse reactions to any substance is known.
	None supplied	No information about adverse reactions to any substance is supplied.
	Please see Appendix A, Known I	ssues

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Global Statement	11

## 3.7 No Known Adverse Reaction to

#### Identification

Label No Known Adverse Reaction to

Metadata Type Data Element Identifier DE-16305

**OID** 1.2.36.1.2001.1001.101.103.16305

#### **Definition**

**Definition** Positive statement about adverse reactions to substances that are explicitly known to have not been identified at the time of recording. **Definition Source** openEHR Foundation **Synonymous Names Data Type** CodeableText **Value Domain** Not specified. In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u><sup>1</sup> with an appropriate object identifier (OID), and **SHALL** be publicly available. When national standard code sets become available, they SHALL be used and the non-standard code sets SHALL be deprecated.

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	01

<sup>1</sup> http://www.hl7.org/oid/index.cfm

## 3.8 No Known Allergic Reaction to

#### Identification

Label No Known Allergic Reaction to

Metadata Type Data Element Identifier DE-16306

**OID** 1.2.36.1.2001.1001.101.103.16306

#### **Definition**

**Definition** Positive statement about allergic reactions to substances that are explicitly known

to have not been identified at the time of recording.

**Definition Source** openEHR Foundation

Synonymous Names

Data Type CodeableText
Value Domain Not specified.

In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u><sup>2</sup> with an appropriate object identifier (OID), and **SHALL** be publicly

available.

When national standard code sets become available, they **SHALL** be used and

the non-standard code sets **SHALL** be deprecated.

## **Usage**

#### **Examples**

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	01

<sup>2</sup> http://www.hl7.org/oid/index.cfm

# 3.9 No Known Hypersensitivity Reaction to

#### Identification

Label No Known Hypersensitivity Reaction to

Metadata Type Data Element Identifier DE-16307

**OID** 1.2.36.1.2001.1001.101.103.16307

#### **Definition**

**Definition** Positive statement about hypersensitivity reactions to substances that are explicitly

known to have not been identified at the time of recording.

**Definition Source** openEHR Foundation

Synonymous Names

Data Type Codeable Text

Value Domain Not specified.

In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u><sup>3</sup> with an appropriate object identifier (OID), and **SHALL** be publicly available.

When national standard code sets become available, they **SHALL** be used and the non-standard code sets **SHALL** be deprecated.

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	01

<sup>3</sup> http://www.hl7.org/oid/index.cfm

## 3.10 No Known Intolerance to

## Identification

Label No Known Intolerance to

Metadata Type Data Element
Identifier DE-16308

**OID** 1.2.36.1.2001.1001.101.103.16308

## **Definition**

**Definition** Positive statement about intolerances to substances that are explicitly known to

have not been identified at the time of recording.

**Definition Source** openEHR Foundation

Synonymous Names

Data Type CodeableText
Value Domain Not specified.

In the absence of national standard code sets, the code sets used **SHALL** be registered code sets, i.e. registered through the <u>HL7 code set registration</u> <u>procedure</u><sup>4</sup> with an appropriate object identifier (OID), and **SHALL** be publicly

available.

When national standard code sets become available, they **SHALL** be used and

the non-standard code sets **SHALL** be deprecated.

## **Usage**

#### **Examples**

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	01

<sup>4</sup> http://www.hl7.org/oid/index.cfm

## 3.11 INFORMATION PROVIDER

#### Identification

Label INFORMATION PROVIDER

Metadata Type Data Group Identifier DG-10296

**OID** 1.2.36.1.2001.1001.101.102.10296

#### **Definition**

**Definition**Details pertinent to the identification of the source of the adverse reaction information.

**Definition Source NEHTA** 

Synonymous Names

Notes This does not have to be a person and, in particular, does not have to be a

healthcare provider. Types of sources include:

· the subject of care;

· a subject of care agent, e.g. parent, guardian;

· the clinician; and

· a device or software.

## **Usage**

Conditions of Use

This **SHALL NOT** be used unless the provider of the information is not the *Composer/Author* of the enclosing Structured Document.

This is a reuse of the *PARTICIPATION* data group, which is described in Participation Data Specification [NEHT2011v].

The following constraints are additional to those specified in Participation Data Specification [NEHT2011v]. Constraints are explained in Appendix B, *Specification Guide for Use*.

• Participation Type **SHALL** have an implementation-specific value equivalent to "Information Provider".

 PERSON OR ORGANISATION OR DEVICE SHALL be instantiated as a PERSON or as a DEVICE.

Conditions of Use Source

**NEHTA** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	01

## **3.12 SUBJECT**

## Identification

LabelSUBJECTMetadata TypeData GroupIdentifierDG-10296

**OID** 1.2.36.1.2001.1001.101.102.10296

## **Definition**

Definition	The individual about whom the adverse reaction information is being recorded.
<b>Definition Source</b>	NEHTA
Synonymous Names	
Scope	Generally only used when the recorder needs to make it explicit. Otherwise, the subject of the enclosing Structured Document is assumed.
Scope Source	NEHTA

## **Usage**

Conditions of Use	This <b>SHALL NOT</b> be used unless the subject of the information is not the <i>Subject of Care</i> of the enclosing Structured Document.
	This is a reuse of the <i>PARTICIPATION</i> data group, which is described in Participation Data Specification [NEHT2011v].
	The following constraints are additional to those specified in Participation Data Specification [NEHT2011v]. Constraints are explained in Appendix B, Specification Guide for Use.
	<ul> <li>Participation Type SHALL have an implementation-specific value equivalent to "Subject".</li> </ul>
	<ul> <li>PERSON OR ORGANISATION OR DEVICE SHALL be instantiated as a PERSON.</li> </ul>
Conditions of Use Source	NEHTA

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	01

# 3.13 Exclusion Statement - Adverse Reactions Instance Identifier

## Identification

Label Exclusion Statement - Adverse Reactions Instance Identifier

Metadata Type Data Element
Identifier DE-16712

**OID** 1.2.36.1.2001.1001.101.103.16712

## **Definition**

Definition
A globally unique object identifier for each instance of an Exclusion Statement Adverse Reactions evaluation.

Definition Source
Synonymous
Names
Data Type
UniqueIdentifier

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	01

## **3.14 LINK**

## Identification

Label LINK

Metadata Type Data Group Identifier DG-16692

**OID** 1.2.36.1.2001.1001.101.102.16692

## **Definition**

**Definition** A link to an instance of another Detailed Clinical Model (DCM) or a document

containing an instance of another DCM.

**Definition Source NEHTA** 

Synonymous Names

Notes Links may be to structures inside the enclosing document or inside other

documents.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	0*

#### Children

Data Type	Name	Occurrences
001011001	Link Nature	11
001011001	Link Role	01
4637	Link Target	11

## 3.15 Link Nature

### Identification

LabelLink NatureMetadata TypeData ElementIdentifierDE-16698

**OID** 1.2.36.1.2001.1001.101.103.16698

## **Definition**

**Definition** The general semantic category of the relationship between this instance of this

DCM, i.e. the source, and the target DCM instance or target document.

**Definition Source NEHTA** 

Synonymous Names

**Notes**This is one of two attributes which together communicate the semantics of the

relationship between the source and target DCMs or document. This attribute is intended to be a coarse-grained category that can be used to enable interoperability

between sender and receiver.

Data Type CodedText

Value Domain Link Nature Values

## **Usage**

Examples 1. is related to

2. is confirmed by or authorised by

3. is related to the same problem or health issue

## Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	LINK	11

## 3.16 Link Nature Values

#### Identification

Link Nature Values Label Metadata Type Value Domain

**Identifier** VD-16698

OID 1.2.36.1.2001.1001.101.104.16698

#### **Definition**

**Definition** The set of values for the general semantic category of the relationship between

this instance of this DCM, i.e. the source, and the target DCM instance or target

document.

**Definition Source NEHTA** 

#### Value Domain

Source ISO 13606-3:2009

**Permissible** Values

The permissible values are those specified in Termlist LINK NATURE in ISO 13606-3:2009 Health informatics - Electronic health record communication - Part 3: Reference archetypes and term lists [ISO2009a]. They are listed here.

LINK-A0, is related to A generic category for any Link, the details of which will be given by the value of Link Role.

LINK-B0, is confirmed by or authorised by

The target link contains [an instance of a DCM or document] that acts as the legal or clinical basis for the activity documented in the source [DCM instance], or is a declaration of intent to provide (or not to provide) requested care. This Link is to be used to connect two [DCM instances or DCM and document], as opposed to the inclusion of a corroborating or authorising participant as an identified party within a single [DCM instance or document].

LINK-C0, is related to the same problem or health issue

The target [instance of a DCM or document] documents health or health care that pertains to the same clinical situation as the source [DCM instance]. One of the two might be defining a problem for which the other is a manifestation, or the relationship might for example be cause and effect, stages in an evolving clinical history, a different interpretation of an observation, a clinical

indication or contraindication.

LINK-D0, is related to the same care plan, act or episode

The source and the target [instances of DCM or documents] are each documenting parts of the same care plan, act or episode. One of the

	two might be defining the same care plan, act or episode, or both might be related milestones.
LINK-E0, is a related documentation	The target [instance of a DCM or document] is an alternative documentary form of the source [DCM instance], such as re-expression of the same clinical information or additional supplementary explanatory information.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Link Nature	11

## 3.17 Link Role

## Identification

LabelLink RoleMetadata TypeData ElementIdentifierDE-16699

**OID** 1.2.36.1.2001.1001.101.103.16699

#### **Definition**

**Definition** The detailed semantic description of the relationship between this instance of this

DCM, i.e. the source, and the target DCM instance or target document.

**Definition Source NEHTA** 

Synonymous Names

Notes This is one of two attributes which together communicate the semantics of the

relationship between the source and target DCMs. This attribute provides for a specific description of the actual role played by the target in relation to the source. This attribute may be populated from any suitable terminology, and therefore might support human readership better than interoperable automated processing.

Data Type CodeableText
Value Domain Link Role Values

## **Usage**

Examples 1. unspecified link

2. suggests

3. endorses

4. evidence for

5. outcome

6. is documented by

7. excerpts

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	LINK	01

## 3.18 Link Role Values

## Identification

LabelLink Role ValuesMetadata TypeValue DomainIdentifierVD-16699

**OID** 1.2.36.1.2001.1001.101.104.16699

## **Definition**

**Definition** The set of values for the detailed semantic description of the relationship between

this instance of this DCM, i.e. the source, and the target DCM instance or target

document.

**Definition Source NEHTA** 

**Context** These values are used within the context of values from *Link Role*. They provide

greater specificity and may be selected more for human readership than for

interoperable automated processing.

Context Source NEHTA

#### **Value Domain**

Source	ISO 13606-3:2009			
Permissible Values	Values <b>SHOULD</b> be from Termlist LINK_ROLE in ISO 13606-3:2009 [ISO2009a].			
values	Values <b>MAY</b> be from a	ny suitable terminology.		
		mlist LINK_ROLE in ISO 13606-3:2009 Health informatics and communication - Part 3: Reference archetypes and term		
	LINK-A1, unspecified link	The term is used when no semantic information is available for this Link in the EHR system from which the EXTRACT has been created.		
	LINK-A2, suggests	The interpretation expressed in the target component is a possible cause or outcome of the findings documented in the source component.		
	LINK-B1, endorses	The interpretation expressed in the source component provides confirmatory evidence or a confirmatory opinion of the interpretation expressed in the target component.		
	LINK-C3, evidence for	The observation or interpretation documented in the source component provides confirmatory evidence of the interpretation expressed in the target component.		
	LINK-D1, outcome	The clinical situation documented in the target component is the direct outcome of the situation documented in the source component.		

LINK-E1, documented by	A clinical situation documented in the source component is more formally documented in the target component.
LINK-E4, excerpts	The source component is an extract (copy) of part or all of the information contained within the target component.

## **Usage**

Conditions of Use	Each of the link terms in LINK_ROLE from ISO 13606-3:2009 is a sub-category of a corresponding term in <i>Link Nature Values</i> , where that correspondence is indicated by the first letter after the code string "LINK-" e.g. the term LINK-A1 is a subcategory of term LINK-A0. If a term in this list is used for the <i>Link Role</i> data element, the appropriate corresponding value <b>SHALL</b> be used from <i>Link Nature Values</i> .
Conditions of Use Source	ISO 13606-3:2009

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
001011001	Link Role	11

# 3.19 Link Target

## Identification

LabelLink TargetMetadata TypeData ElementIdentifierDE-16700

**OID** 1.2.36.1.2001.1001.101.103.16700

## **Definition**

**Definition** The logical "to" object in the link relation, as per the linguistic sense of the *Link* 

Nature data element (and, if present, the Link Role data element).

**Definition Source NEHTA** 

Synonymous Names

Data Type Link

UniqueIdentifier

## **Usage**

**Examples** 

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	LINK	11

## 3.20 Detailed Clinical Model Identifier

## Identification

Label Detailed Clinical Model Identifier

Metadata Type Data Element Identifier DE-16693

**OID** 1.2.36.1.2001.1001.101.103.16693

## **Definition**

**Definition** The NEHTA OID for the Exclusion Statement - Adverse Reactions concept

represented by this DCM.

**Definition Source NEHTA** 

Synonymous Names

Data Type UniqueIdentifier

## **Usage**

**Examples Default Value**1.2.36.1.2001.1001.101.102.16137

Default Value Conditions of Use The value of this item is fixed and **SHALL** be the default value.

# Relationships

#### **Parents**

Data Type	Name	Occurrences (child within parent)
	EXCLUSION STATEMENT - ADVERSE REACTIONS	11

This page is intentionally left blank.

nehta Known Issues

# **Appendix A. Known Issues**

This appendix lists known issues with this specification at the time of publishing. NEHTA is working on solutions to these issues, and we encourage comments to further assist with the development of these solutions.

Reference	Description
Data Hierarchy	Only the parts of these DCMs required for current Structured Content Specifications have been mapped to HL7 CDA. Mapping the remaining parts to CDA may reveal inconsistencies in the data hierarchies, requiring normative change.
Clinical Manifestation Values	The Clinical Manifestation Values has not been defined. Until it is defined use the Clinical finding foundation reference set (SNOMED CT-AU Concept ID: 32570071000036102).
Quantity Data Element	The correctness of the solution presented in this specification is uncertain; this data element needs to be able to cater for quantities of non-medications.
Anatomical Site Data Element	In the future this data element needs to be updated in order to cater for administration of non-medications.
Global Statement Values Data Element	The list of permissible values is a sample set to initiate discussion and collaboration to develop the correct set of values.
Exclusion Statement	The Exclusion Statement DCMs are the subject of ongoing development and review and may well change in the future.
Undefined Value Domains	The following data elements lack a defined value domain: Numerical Identifier, Anatomical Plane, Anatomical Location Aspect, Reaction Type, Identified Landmark, Intervention Day of Week, No Known Adverse Reaction to, No Known Allergic Reaction to, No Known Hypersensitivity Reaction to, and No Known Intolerance to.
	NEHTA is in the process of developing national code sets for these items. In the meantime, you are free to use your own code set(s), providing any code set used <b>SHALL</b> be registered, i.e. registered through the HL7 code set registration procedure with an appropriate object identifier (OID), and <b>SHALL</b> be publicly available. Note that when national standard code set(s) do become available, they <b>SHALL</b> be used and the non-standard code sets <b>SHALL</b> be deprecated.
Undefined Data Structures	The following data elements lack a defined data structure: Intravenous Administration Details and Reporting Details.
	A free-text data element is currently used as an interim solution.

This page is intentionally left blank.

# Appendix B. Specification Guide for Use

## **B.1 Overview**

Each Detailed Clinical Model (DCM) and Structured Content Specification (SCS) is designed to be a shared basis for data interpretation. It specifies rigorous business and technical definitions of data which systems may need to share. It is intended to be a logical specification of the data to be persisted within or communicated between systems. It is also the foundation for conformance, compliance and accreditation testing of implemented systems. NEHTA's CDA implementation guides are guides to the implementation of HL7 CDA R2 messages based upon these DCMs and SCSs.

Each DCM specifies all of the data components required for any use of a clinical concept, for instance an entry in a medical record such as a procedure or an imaging test. As such, they are maximal data sets. DCMs are building blocks which are trimmed to size for use in the construction of SCSs.

Each SCS specifies the data for a single type of clinical document or information exchange, such as a discharge summary. It is assembled using DCMs that have been constrained to eliminate data components not relevant to the particular context. For example, *Procedure* in a discharge summary uses only some of the data components required by *Procedure* in a specialist report.

# **B.2 The Structured Content Specification Metamodel**

The NEHTA Structured Content Specification Metamodel (see Figure 1) is used to specify the overall structure of a Structured Content Specification.

A DCM can be regarded as a data group with no parent.




Figure 1: SCS Metamodel

There are two main components used to organise information within an SCS as follows:

Context: This contains information related to the overall context of the document.

Content: This contains information that changes between different SCSs, but is always structured as shown, and consists of the following components:

- Section
- · Data Group
- · Data Element
- · Value Domain

These components are described in more detail below.

#### **Context**

The purpose of the context is to identify and classify the document and to provide subjects of care and involved healthcare providers with the information related to the relevant healthcare events.

#### Content

Content contains a collection of personal information and health information pertinent to a subject of care which is derived from the healthcare event described in the document. The detail is organised into one or more data groups which are optionally grouped into sections.

#### Section

A section is composed of other sections, data groups, or both. It is an organising container that gives the reader a clue as to the expected content. The primary purpose of a section is to organise information in a manner that is suitable for the primary purpose for which it is collected, and to provide a way to navigate through the data components within the document, thereby enabling more efficient querying. It is recommended that the section support safe reuse for secondary purposes, e.g. clinical coding or inclusion in a summarised form in an electronic health record. A section is context-specific to the document in which it resides.

## **Data Group**

Each data group is used to represent one concept. A data group consists of other data groups or data elements (or both). Some data groups are reused across DCMs.

Every instance of a data group SHALL have at least one child data component instantiated.

## **Participation**

Participation is a special case of a data group that is based on a data group template, which is reused throughout the DCMs and SCSs. Participations are an amalgam of the Actors (see below) operating within a defined healthcare domain and the Roles they are playing within that domain.

A Participant has been defined to align with the concepts of the NEHTA interoperability framework [NEHT2007b]. It equates to an *Entity* that is related to the action described in an SCS as an *Actor*. A participant can be a human, an organisation or an IT system.

[NEHT2011v] defines the full Participation specification.

## **Choice**

Choice represents a decision to be made at run-time between a disjunctive mandatory set of data groups defined at design-time, i.e. one and only one member of the set is chosen for each instance of the choice.

For example, at design time a Healthcare Provider provides a service but it is not until run-time that a decision can be made as to whether the provider is a person or an organisation. Hence when a Healthcare Provider Participant is instantiated, it will contain either an instance of the *Person* data group or an instance of the *Organisation* data group.

#### **Data Element**

A data element is the smallest named unit of information in the model that can be assigned a value. For example, *DateTime of Observation* and *Observation Note*. Data elements are bound to data types (see Data Types Legend). Some data elements are reused in different data groups.

Whilst all data elements are constrained by their data type, some data elements are further constrained by value domains (see Value Domain below).

## **Value Domain**

A value domain constrains the permissible values for a data element. The values are often a subset of values based on a generic data type.

Value domains are reusable components and therefore, the same value domain can be referred to by different data elements in different contexts. Value domains are often specified as a reference set. A reference set (or a subset) is a constrained list of SNOMED CT-AU, AMT or LOINC concepts that are appropriate to a particular context. It is noted that many of these reference sets have been developed specifically for the context in which they appear. It is recommended that an assessment of fitness for purpose be undertaken before using any of the reference sets in another context.

Value domains constrain by either specifying a lower or upper bound (or both) on the range of permissible values or else by specifying a finite set of prescribed values. Such a set of prescribed values can be specified directly within the definition of the data element, or in a separate but associated specification or else by reference to one or more vocabulary/terminology reference sets. The table below provides some examples of value domains.

**Table 1: Value Domain Examples** 

Data Element	Data Type	Example	of Value Domain
Sex	CodedText	[SA2006a] and [SA2006b] derive their values from METeOR 270263 which includes values such as:	
		Value	Meaning
		1	Male
		2	Female
		3	Intersex or Indeterminate
		9	Not Stated/Inadequately Described
Diagnosis	CodeableText		ED CT-AU reference set which references concepts Bronchitis' (Concept ID: 32398004).
Therapeutic Good Identification	CodeableText	'Ibuprofen	eference set which references concepts such as Blue (Herron) (ibuprofen 200 mg) tablet: film-coated, Concept ID: 54363011000036107).
Individual Pathology Test Result Name	CodeableText	A LOINC subset which references concepts such as 'Cholesterol [Moles/volume] in Serum or Plasma' (ID: 14647-2).	

## **B.3 Icon Legend**

These legends describe all icons that are used within the various NEHTA information specifications.

## **Metadata Types Legend**

The following table explains each of the icons used to represent the metadata types within DCMs and SCSs.

**Table 2: Metadata Types Legend** 

Icon	Metadata Types
	Structured Document
	Section
	Data Group
8	Participation
	Choice

## **Data Types Legend**

The following table explains each of the icons used to represent the data types bound to each data element in the SCSs. These data types are a profile of the **ISO 21090-2011** data types as specified in [NEHT2010c].

**Table 3: Data Types Legend** 

lcon	Data type	Explanation
4	Boolean	A primitive data type, sometimes called the logical data type, having one of two values: <i>true</i> and <i>false</i> . Many systems represent true as <i>non-zero</i> (often
	(ISO 21090: BL)	
		Usage/Examples
		• An actual value entered by a user might be "yes" or could be chosen by a mouse click on an icon such as <b>☑</b> .



#### CodeableText

(ISO 21090: CD)

Coded text with exceptions; a flexible data type to support various ways of holding text, both free text and coded text. Commonly used to support compliance for early adopters of the Structured Content Specifications. While it is recommended that the values in this data type come from the bound value domain, it allows other value domains to also be used (with or without translations to the bound value domain) or free text alternatives. This is a recognition that it may not be possible to define an entire value domain for a complex concept (e.g. *Diagnosis*) or that there may be competing code sets in existence. Note that within exchange specifications or message profiles this data type **MAY** be constrained to mandate compliance with the bound value domain.

#### Usage/Examples

- AIHW Separation Mode specifies the status at separation of a person from an organisation. An early adopter MAY have a similar concept (coded or otherwise) that maps to this data element but does not strictly comply with the AIHW values.
- A SNOMED CT-AU coded/complex expression that embodies single or multiple concepts. The SNOMED CT-AU concepts behind these CodeableText components are specified in the Structured Content Specification value domains.



#### CodedText

(ISO 21090: CD)

Coded text *without* exceptions; text with code mappings. Values in this data type **SHALL** come from the bound value domain, with no exceptions. Often used for reference sets with only a small number of applicable values, e.g. Gender and Document Status.

#### Usage/Examples

[SA2006b] specifies the following value domain representing a type of address:

Value	Meaning
1	Business
2	Mailing or Postal
3	Temporary Accommodation
4	Residential (permanent)
9	Not Stated/Unknown/Inadequately Described



#### DateTime

(ISO 21090: TS)

Used for specifying a single date or time (or both). Has the ability to indicate a level of precision, but not whether the date or time is estimated. String representations of known dates **SHALL** conform to the nonextended format within the **ISO 21090-2011** standard, i.e. YYYYMMDDHHMMSS.UUUU[+]-ZZzz.

#### Usage/Examples

- Partial dates: 2008, 20081001.
- To indicate 1:20 pm on May the 31st, 1999 for a time zone which is 5 hours behind Coordinated Universal Time (UTC): 19990531132000-0500.



#### Duration

(ISO 21090: PQ.TIME)

The period of time during which something continues. Consists of a value and a unit which represents the time value, e.g. hours, months. Compound durations are not allowed, e.g. 10 days 3 weeks 5 hours.

#### **Usage/Examples**

- 3 hours
- · 6 months
- 1 year



#### Any

(ISO 21090: ANY) Represents a data element where the data type to be used is conditional on another data component. The values that can be required will vary considerably depending on the context. Note that this is an abstract data type that is the basis for all data types and **SHOULD NOT** be used in an actual implementation.



#### EncapsulatedData

(ISO 21090: ED)

Data that is primarily intended for human interpretation or for further machine processing outside the scope of this specification. This includes unformatted or formatted written language, multimedia data, or structured information as defined by a different standard (e.g. XML signatures).

#### **Usage/Examples**

- · JPEG images
- · HTML documents
- [RFC1521] MIME types



#### Integer

(ISO 21090: INT)

The mathematical data type comprising the exact integral values (according to [NEHT2010c]).

#### **Usage/Examples**

- 1
- -50
- 125



Link

(ISO 21090: TEL) This is a general link, reference or pointer to an object, data or application that exists logically or is stored electronically in a computer system.

#### Usage/Examples

- URL (Uniform Resource Locator) the World Wide Web address of a site
  on the internet, such as the URL for the Google internet search engine –
  http://www.google.com.
- An absolute or relative path within a file or directory structure e.g. in the Windows® operating system, the "link" or absolute path to a particular letter could be C:\Documents and Settings\GuestUser\MyDocuments\letter.doc



#### Quantity

(ISO 21090: PQ)

Used for recording many real world measurements and observations. Includes the magnitude value and the units.

#### Usage/Examples

- · 100 centimetres
- 25.5 grams



#### QuantityRatio

(ISO 21090: RTO) The relative magnitudes of two *Quantity* values (usually expressed as a quotient).

#### **Usage/Examples**

- 25 mg/500 ml
- · 200 mmol per litre



#### QuantityRange

(ISO 21090: IVL)

Two *Quantity* values that define the minimum and maximum values, i.e. lower and upper bounds. This is typically used for defining the valid range of values for a particular measurement or observation. Unbounded quantity ranges can be defined by not including a minimum and/or a maximum quantity value.

#### Usage/Examples

- -20 to 100 Celsius
- 30-50 mg
- >10 kg



#### Real

(ISO 21090: REAL) A computational approximation to the standard mathematical concept of real numbers. These are often called floating-point numbers.

#### **Usage/Examples**

- 1.075
- -325.1
- 3.14157



#### Text

(ISO 21090: ST)

Character strings (with optional language). Unless otherwise constrained by an implementation, can be any combination of alpha, numeric or symbols from the Unicode character set. Sometimes referred to as free text.

#### Usage/Examples

"The patient is a 37 year old man who was referred for cardiac evaluation after complaining of occasional palpitations, racing heart beats and occasional dizziness."



#### TimeInterval

(ISO 21090:TS)

An interval in time, with (optionally) a start date/time and (optionally) an end date/time and/or a duration/width.

#### **Usage/Examples**

- 01/01/2008 31/12/2008
- 1:30 a.m. 6:00 p.m., duration/width = 16.5 hours



UniqueIdentifier

A general unique value to identify a physical or virtual object or concept.

(ISO 21090: II)

In using this data type, the attributes of the UniqueIdentifier data type **SHOULD** be populated from the identifiers as defined in AS 4846 (2006) [SA2006a] and AS 5017 (2006) [SA2006b] as follows:

- root: a globally unique object identifier that identifies the combination of geographic area, issuer and type. If no such globally unique object identifier exists, it SHALL be created.
- extension: a unique identifier within the scope of the root that is directly equivalent to the identifier designation element.
- identifierName: a human readable name for the namespace represented by the root that is populated with the issuer or identifier type values, or a concatenation of both, as appropriate. The content of this attribute is not intended for machine processing and SHOULD NOT be used for that purpose.
- identifierScope: the geographic span or coverage that applies to or constrains the identifier. It is directly equivalent to the geographic area element. The content of this attribute is not intended for machine processing and SHOULD NOT be used as such.

Also, the following constraints apply on the UniqueIdentifier data type:

- 1. The *root* attribute **SHALL** be used.
- 2. For an entity identifier, the *root* attribute **SHALL** be an OID that consists of a node in a hierarchically-assigned namespace, formally defined using the ITU-T's ASN.1 standard.
- 3. For an entity identifier, the *root* attribute **SHALL NOT** be a UUID.
- 4. The extension attribute SHALL be used.

#### **Usage/Examples**

IHIs, HPI-Is, HPI-Os and patient hospital medical record numbers are examples of identifiers that **MAY** be carried by this data type.

## **Keywords Legend**

Where used in this document and in DCMs and SCSs, the keywords **SHALL**, **SHOULD**, **MAY**, **SHALL NOT** and **SHOULD NOT** are to be interpreted as described in [RFC2119].

The following table defines these keywords.

Table 4: Keywords Legend

Keyword	Interpretation
SHALL	This word, or the term 'required', means that the statement is an absolute requirement of the specification.
SHOULD	This word, or the adjective 'recommended', means that there <b>MAY</b> exist valid reasons in particular circumstances to ignore a particular component, but the full implications <b>SHALL</b> be understood and carefully weighed before choosing a different course.

MAY	This word, or the adjective 'optional', means that a component is truly optional. One implementer may choose to include the component because a particular implementation requires it, or because the implementer determines that it enhances the implementation, while another implementer may omit the same component. An implementation that does not include a particular option <b>SHALL</b> be prepared to interoperate with another implementation that does include the option, perhaps with reduced functionality. In the same vein, an implementation that does include a particular option <b>SHALL</b> be prepared to interoperate with another implementation that does not include the option (except of course, for the feature the option provides).
SHALL NOT	This phrase means that the statement is an absolute prohibition of the specification.
SHOULD NOT	This phrase, or the phrase 'not recommended' means that there <b>MAY</b> exist valid reasons in particular circumstances when the particular behaviour is acceptable or even useful, but the full implications <b>SHOULD</b> be understood and the case carefully weighed before implementing any behaviour described with this label.

## **Obligation Legend**

Obligation in DCMs or SCSs specifies whether or not a data component **SHALL** be populated in the logical record architecture of a message. NEHTA intends that all data components will be implemented.

Implementation guides specify the rules and formats for implementing and populating data components in specific messaging formats.

The following table defines the obligations.

**Table 5: Obligations Legend** 

Keyword	Interpretation
ESSENTIAL	Indicates that the data component is considered a mandatory component of information and <b>SHALL</b> be populated.
	Usage/Examples:
	The Participant component for a Subject of Care <b>SHALL</b> include an Entity Identifier data component in order to hold the IHI.
OPTIONAL	Indicates that the data component is not considered a mandatory component of information and <b>MAY</b> be populated.
	Usage/Examples:
	This is only needed when a DCM incorrectly asserts that a data component is <b>ESSENTIAL</b> . It will be used with a note stating that the DCM needs revision.
PROHIBITED	Indicates that the data component is considered a forbidden component of information and <b>SHALL NOT</b> be populated.
	Usage/Examples:
	Within a Participation data group depicting a Subject of Care, the Participation Healthcare Role <b>SHALL NOT</b> be completed.

#### **CONDITIONAL**

Indicates that a data component is considered **ESSENTIAL** only on satisfaction of a given condition. Individual data components specify the obligation of the data component when the condition is not met.

When a condition is met, the data component is considered to be **ESSENTIAL** and **SHALL** be populated.

When a condition is not met, the data component may be considered as **PROHIBITED**, or the data component may be considered **OPTIONAL**.

#### Usage/Examples:

Within a Pathology Result Report, the *Specimen Detail* data group is **ESSENTIAL** if the requested test is to be performed on a specimen, otherwise it **SHALL NOT** be populated.

Where **ESSENTIAL** child data components are contained within **OPTIONAL** parent data components, the child data components only need to be populated when the parent is populated.

# **B.4 Information Model Specification Parts Legends**

This section illustrates the format and parts used to define each section, data group and data element within NEHTA's information model specifications and identifies when each part is applicable.

## **Data Hierarchy**

The top-level component contains a data hierarchy. Each row contains information about a single data component. The entries are nested to represent inclusion of one component in another. Each entry contains at least three occupied cells. The left-most cell contains an icon to indicate the entry's data type. The next cell to the right contains the label and description of the component (if the label is different from the name, the name is displayed in brackets after the label). The next cell to the right contains the multiplicity range for the data component.

The right-hand side of the data hierarchy may contain one or more columns under the heading "Core Requirement". Each column contains information for one document exchange scenario. A cell that is empty indicates that the data component on that row is **OPTIONAL** to implement. That is, software that creates documents made in conformance with this specification **MAY** exclude the data component; and software that reads documents made in conformance with this specification **MAY** ignore the data component. All other components **SHALL** be implemented.

In an SCS, a component may be prohibited, that is, it occurs in the referenced DCM but it **SHALL NOT** be included in documents created according to the SCS. This is represented by a multiplicity range of 0..0. The text of the entry is also in a strike through font and it has a grey background.

## **Chapter Name**

Each section, data group, data element, value domain or choice has its own eponymous chapter. The chapter name is used in all data hierarchies.

## **Identification Section Legend**

The following table illustrates the layout of the Identification section and describes the various parts of the section.

## **Table 6: Identification Section Legend**

Label A suggested display name for the component. (Source NEHTA.)

Metadata Type The type of the component, e.g. section, data group or data element. (Source NEHTA.)

Identifier A NEHTA assigned internal identifier of the concept represented by the component. (Source NEHTA.)

OID An object identifier that uniquely identifies the concept represented by the data component. (Source NEHTA.)

External Identifier An identifier of the concept represented by the data component that is assigned by an organisation other than NEHTA. (Source NEHTA.)

## **Definition Section Legend**

The following table illustrates the layout of the Definition section and describes the various parts of the section.

## **Table 7: Definition Section Legend**

Definition	The meaning, description or explanation of the data component. (Source NEHTA.)
	For data groups used in a particular context, the definition <b>MAY</b> be a refinement of the generic data group definition.
<b>Definition Source</b>	The authoritative source for the Definition statement.
Synonymous Names	A list of any names the data component <b>MAY</b> also be known as. (Source NEHTA.)
	Implementers <b>MAY</b> prefer to use synonymous names to refer to the component in specific contexts.
Scope	Situations in which the data component may be used, i.e. the extent and capacity within which this data component may be used, including the circumstances under which the collection of specified data is required or recommended.
	For example, Medication Instruction (data group) has a scope which includes all prescribable therapeutic goods, both medicines and non-medicines.
	This attribute is not relevant to data elements or value domains. (Source NEHTA.)
Scope Source	The authoritative source for the Scope statement.
Context	The environment in which the data component is meaningful, i.e. the circumstance, purpose and perspective under which this data component is defined or used.

	For example, Street Name has a context of Address. (Source NEHTA.)
Assumptions	Suppositions and notions used in defining the data component. (Source NEHTA.)
<b>Assumptions Source</b>	The authoritative source for the Assumptions statement.
Notes	Informative text that further describes the data component, or assists in the understanding of how the data component can be used. (Source NEHTA.)
<b>Notes Source</b>	The authoritative source for the Notes statement.
Data Type	The data type of the data element, e.g. DateTime or Text. (Source NEHTA.)
	The data type is applicable only to data elements.
	The valid data types are specified in the Data Types Legend.
Value Domain	The name and identifier of the terminologies, code sets and classifications to define the data element value range, or a statement describing what values to use in the absence of a defined value domain for the related data element.
	In the absence of national standard code sets, the code sets used <b>SHALL</b> be registered code sets, i.e. registered through the HL7 code set registration procedure with an appropriate object identifier (OID), and <b>SHALL</b> be publicly available.
	When national standard code sets become available, they <b>SHALL</b> be used and the non-standard code sets <b>SHALL</b> be deprecated. (Source NEHTA.)
	The Value Domain is applicable only to CodedText and CodeableText data elements.

## **Value Domain Section Legend**

The following table illustrates the layout of the Value Domain section and describes the various parts of the section.

## **Table 8: Value Domain Section Legend**

Source	The name of the terminology or vocabulary from which the value domain's permissible values are sourced, e.g. SNOMED CT-AU, LOINC.
Version Number	Version number of the value domain source.
Permissible Values	List of permissible values in the value domain.

## **Usage Section Legend**

The following table illustrates the layout of the Usage section and describes the various parts of the section.

## **Table 9: Usage Section Legend**

Examples	One or more demonstrations of the data that is catered for by the data element.
	(Source NEHTA.)

	Where a data element has an associated value domain, examples representative of that domain are used where possible. Where the value domain is yet to be determined, an indicative example is provided.
	Implementation guides <b>MAY</b> contain specific examples for how data elements <b>SHALL</b> be populated and how they relate to each other.
	The Value Domain is applicable only to CodedText and CodeableText data elements.
Conditions of Use	Prerequisites, provisos or restrictions for use of the component. (Source NEHTA.)
Conditions of Use Source	The authoritative source for the Conditions of Use statement.
Misuse	Incorrect, inappropriate or wrong uses of the component. (Source NEHTA.)
Default Value	A common denomination, or at least a usable denomination, from the Value Domain where available or applicable, typically assigned at the creation of an instance of the component. (Source NEHTA.)

## **Relationships Section Legend**

The Relationships section specifies the cardinality and conditionality between parent and child data components. Note that if no components in either table have any conditions, then the condition column will be omitted for that table.

The following table illustrates the layout of the Parent relationships table. Note that the occurrences and conditions in the relationships described by this table are from the parent to the child component, i.e. from the component listed in the table to the component described by the section.

Table 11: Parent Legend

Data Type	Name	Occurrences (child within parent)	Condition
The icon illustrating the metadata type or data type.		The minimum and maximum number of instances of the component described on this page that <b>SHALL</b> occur.	The conditions that <b>SHALL</b> be met to include the data element. Only applicable for elements with a conditional obligation.

The following table illustrates the layout of the Children relationships table.

Table 10: Children Legend

Data Type	Name	Occurrences	Condition
The icon illustrating the metadata type or data type.		The minimum and maximum number of instances of the component described on this page that <b>SHALL</b> occur.	The conditions that <b>SHALL</b> be met to include this child data element. Only applicable for elements with a conditional obligation.

nehta Change History

# **Appendix C. Change History**

## C.1 Changes Introduced in this Version

## **Preliminary Pages**

Added the section "Included Detailed Clinical Models" to provide identification of the version of each DCM included in this specification.

Corrected "Australian Institute of Health & Welfare" to "Australian Institute of Health and Welfare".

## **Chapter 1 Introduction**

This chapter has been revised through editorial review, a number of editorial and typographical errors have been corrected.

Added footnote to 1.1 Purpose and Scope to provide a reference defining the concept "Level 4 (semantic) interoperability".

# **Chapter 2 Adverse Reaction Detailed Clinical Model**

Added a sentence identifying the version of the DCM.

Corrected presentation of data component names in text throughout the chapter.

Added standard examples text for all data components of type DateTime.

Corrected "eg Gentamycin" to "e.g. Gentamicin" in 2.1 Purpose.

Corrected over capitalisation in 2.2 Use and 2.3 Misuse.

Amended 2.2 Use to include a further sentence of explanatory text and replaced "contra-indication" with "contraindication".

Added a comma (,) to the 3<sup>rd</sup> list item in 2.3 Misuse.

The Adverse Reaction UML Class Diagram has been moved to this chapter and updated to reflect changes to the included data components; the explanative text has been slightly reworded.

Primarily to support the Consolidated View in the PCEHR the following data components (sourced from the openEHR Reference Model) have been added:

- a. Adverse Reaction Instance Identifier
- b. LINK
  - i. Link Nature
  - ii. Link Role
  - iii. Link Target
- c. Detailed Clinical Model Identifier

The structure of the tables within the relationships sections of each data component has been modified to remove the condition column and change the title of the "Occurrences" column in the Parents table to "Occurrences (child within parent)".

Corrected the case of the synonymous names and the OID and identifier of ADVERSE REACTION.

Corrected the presentation of permissible values and replaced "patient" with "subject of care" in the definition of Substance/Agent Values .

Replaced "True" with " 'true' " in the conditions of use of Absolute Contraindication.

Renamed *Clinical Manifestation Values Reference Set* to *Clinical Manifestation Values*, and included explanative text for permissible values.

Corrected "Idiosyncracy" to "Idiosyncrasy" in the examples of Reaction Type.

Inserted "the" in the definition, replaced "may be" with "is" and "reaction which warrants" with "reaction that warrants" in the notes of Adverse Reaction Certainty.

Corrected presentation of the usage section for Adverse Reaction Certainty Values.

Renamed *ADDITIONAL REACTION DETAIL* (Label: Additional Reaction Detail) to ANATOMICAL LOCATION (Label: Additional Reaction Detail).

Corrected the use of "and/or" in:

- a. Manifestation
- b. Adverse Reaction Certainty
- c. Reaction Onset Date
- d. Earliest Exposure
- e. Quantity

Corrected the article to "the" in the definition of:

- a. Anatomical Location Name
- b. Identified Landmark
- c. Anatomical Location Description
- d. Side
- e. Laterality Reference Set

nehta Change History

Corrected presentation of examples for:

- a. Manifestation
- b. Reaction Type
- c. Adverse Reaction Certainty
- d. Reaction Description
- e. Dose Unit
- f. Route
- g. Medication Delivery Method
- h. Side
- i. Numerical Identifier
- j. Anatomical Plane
- k. Visual Markings/Orientation

Corrected "Bilalteral" to "Bilateral" in the examples of Side.

Replaced "Identify the specific anatomical site out of multiple sites" with "An ordinal number that identifies the specific anatomical site from multiple sites" in the definition of Numerical Identifier.

Inserted an "a" and replaced "Qualifiers" with "Qualifier(s)"in the Definition of RELATIVE LOCATION.

Corrected "medial" to "lateral" in the examples of Anatomical Location Aspect.

Replaced "Image" with "An image" in the definition of Anatomical Location Image.

Made each of the children of the ADDITIONAL EXPOSURE DETAIL choice optional to align with the correct representation of choices.

Amended the scope of AMOUNT OF MEDICATION.

Changed the data types of Quantity from (Real, QuantityRatio) to (Real, Quantity).

Corrected "Mg" to "mg" in the examples of Dose Unit.

Removed the notes from of Dose Unit Reference Set.

Inserted a "the" in the notes of TIMING.

Added a condition of use to Intervention Time.

Amended the note of Intervention Day of Month.

Changed the label of MEDICATION ADMINISTRATION from "Exposure Mechanism" to "MEDICATION ADMINISTRATION".

Corrected "neubliser" to "nebuliser" in the examples of Medication Delivery Method.

Corrected the case for synonymous names and improved the wording of the note in Route.

Corrected the representation of the Intravenous Administration Details data component to be a *Text* data element and corrected its OID and identifier.

Corrected the OID and identifier of Reporting Details.

Amended wording of the example in Dose Duration.

Corrected "Link to further information about about the presentation ..." to "Link to further information about the presentation..." in the definition of Supporting Clinical Record Information and amended the note.

All instances of "have a fixed value of" have been replaced with "have an implementation-specific value equivalent to".

Amended the note of INFORMATION PROVIDER.

# **Chapter 3 Exclusion Statement - Adverse Reactions Detailed Clinical Model**

Added a sentence identifying the version of the DCM.

Added 3.1 Purpose and 3.2 Use.

Corrected the definition and removed usage in toto from EXCLUSION STATEMENT - ADVERSE REACTIONS.

The Exclusion Statement - Adverse Reactions UML Class Diagram has been moved to this chapter and updated to reflect the changes in the data components; the explanative text has been slightly reworded.

Primarily to support the Consolidated View in the PCEHR the following data components (sourced from the openEHR Reference Model) have been added:

- a. Exclusion Statement Adverse Reactions Instance Identifier
- b. LINK
  - i. Link Nature
  - ii. Link Role
  - iii. Link Target
- c. Detailed Clinical Model Identifier

The structure of the tables within the relationships sections of each data component has been modified to remove the condition column and change the title of the "Occurrences" column in the Parents table to "Occurrences (child within parent)".

Corrected the list of permissible values for Global Statement.

Amended the note of INFORMATION PROVIDER.

All instances of "have a fixed value of" have been replaced with "have an implementation-specific value equivalent to".

## **Chapter 4 UML Class Diagram**

Chapter 4 removed and the content moved to Chapter 2 and Chapter 3 as appropriate.

## **Appendix A Known Issues**

Removed entry for 'Intervention Day of Week' data element in line with the decision to define a value domain for this data element.

Corrected the entry for 'Undefined Value Domains' to include all applicable data components.

Added entry for clinical manifestation values.

nehta Change History

Amended entry for 'Quantity' data element to take into account changes to the data element.

Added undefined data structures entry to indicate the data elements that lack a defined data structure.

## **Appendix B Guide for Use**

This appendix has revised through editorial review, a number of editorial and typographical errors have been corrected.

In 'Value Domain' in B.2 "To Be Advised" replaced with "Individual Pathology Test Result Name".

Added 'Obligation Legend' in B.3.

Reworked 'Data Hierarchy' in B.4 to explain 'Core Requirement'.

Reworked 'Relationships Section Legend' in B.4 to include further explanative text, and improved tables.

## **Appendix C Change History**

This is a new appendix included to provide detailed information of the changes between the previous version of this specification and the current version of this specification.

#### Reference List

This chapter has been moved to after the appendices.

Added entry for reference cited in footnote added to section 1.1.

Added entry for Harmonisation in Pharmacovigilance.

Added entry for The use of the WHO-UMC system for standardised case causality assessment.

Added entry for ISO 13606-3:2009.

Added entry for NEHTA Interoperability Framework.

Removed entry for Data Specifications and Structured Document Templates - Guide for Use, Version 1.2 which is replaced by Appendix B, *Specification Guide for Use*.

Corrected the titles of AS 4846 and AS 5017.

This page is intentionally left blank.

nehta Reference List

## **Reference List**

[EDWA1994a] I. Ralph Edwards, Cecilia Biriell, , 1994, Harmonisation in Pharmacovigilance, Drug Safety, 10.2, accessed 14 December 2011. http://www.who-umc.org/graphics/25253.pdf [ISO2009a] International Organization for Standardization, 14 Jan 2009, ISO 13606-3:2009 Health informatics - Electronic health record communication - Part 3: Reference archetypes and term lists, Edition 1 (Monolingual), accessed 20 June 2012. https://infostore.saiglobal.com/store/Details.aspx?ProductID=1092099 [NEHT2005a] National E-Health Transition Authority, 25 May 2005, NEHTA Acronyms, Abbreviations & Glossary of Terms, Version 1.2, accessed 20 September 2012. http://www.nehta.gov.au/component/docman/doc\_download/-8-clinical-information-glossary-v12 [NEHT2007b] National E-Health Transition Authority, 24 September 2007, Interoperability Framework, Version 2.0. http://www.nehta.gov.au/connecting-australia/ehealth-interoperability [NEHT2010c] National E-Health Transition Authority, September 2010, Data Types in NEHTA Specifications: A Profile of the ISO 21090 Specification, Version 1.0, accessed 1 February 2013. http://www.nehta.gov.au/component/docman/doc\_download/-1121-data-types-in-nehta-specifications-v10 [NEHT2011v] National E-Health Transition Authority, 20 July 2011, Participation Data Specification, Version 3.2, accessed 20 September 2012. http://www.nehta.gov.au/component/docman/doc\_download/-1341-participation-data-specification-v32 [RFC1521] Network Working Group, 1993, RFC1521 - MIME (Multipurpose Internet Mail Extensions) Part One, accessed 07 June 2010. http://www.fags.org/rfcs/rfc1521.html [RFC2119] Network Working Group, 1997, RFC2119 - Key words for use in RFCs to Indicate Requirement Levels, accessed 13 April 2010. http://www.fags.org/rfcs/rfc2119.html [SA2006a] Standards Australia, 2006, AS 4846 (2006) - Health Care Provider Identification, accessed 12 November 2009. http://infostore.saiglobal.com/store/Details.aspx?ProductID=318554 Standards Australia, 2006, AS 5017 (2006) - Health Care Client Identification, ac-[SA2006b] cessed 12 November 2009. http://infostore.saiglobal.com/store/Details.aspx?ProductID=320426 [UMC2011a] The Uppsala Monitoring Centre, The use of the WHO-UMC system for standardised case causality assessment, accessed 14 December 2011. http://who-umc.org/graphics/24734.pdf [WALJ2005a] Walker et al., , January 2005, The Value Of Health Care Information Exchange And Interoperability, Health Affairs, 2005, accessed 22 November 2011. http://content.healthaffairs.org/content/early/2005/01/19/hlthaff.w5.10.short

This page is intentionally left blank.

nehta Index

Todox	DE-15554, 19
Index	DE-15563, 24
	DE-15564, 17
Λ	DE-15568, 21
<b>A</b>	DE-15590, 13
Absolute Contraindication, 12	DE-16073, 12
ADDITIONAL EXPOSURE DETAIL, 47	DE-16153, 29
Additional Reaction Detail, 27	DE-16199, 43
ADVERSE REACTION, 6	DE-16302, 95
Adverse Reaction Certainty, 21	DE-16305, 97
Adverse Reaction Certainty Values, 22	DE-16306, 98
Adverse Reaction Comment, 13	DE-16307, 99
Adverse Reaction Event Comment, 72	DE-16308, 100
Adverse Reaction Instance Identifier, 80	DE-16319, 41
Adverse Reaction Report, 74	DE-16336, 31
AMOUNT OF MEDICATION, 48	DE-16338, 33
ANATOMICAL LOCATION, 27	DE-16340, 35
Anatomical Location Aspect, 38 Anatomical Location Description, 41	DE-16343, 37
Anatomical Location Image, 43	DE-16345, 38
Anatomical Location Name, 29	DE-16346, 40
Anatomical Plane, 35	DE-16349, 16
Anatomical Site, 64	DE-16352, 26
Aspect, 38	DE-16372, 45
Aspect, 30	DE-16373, 46
В	DE-16376, 70
_	DE-16379, 73
Body Structure Foundation Reference Set, 30, 65	DE-16407, 42
•	DE-16470, 66
C	DE-16471, 67 DE-16477, 44
Certainty, 21	DE-16482, 69
Choice	DE-16483, 72
ADDITIONAL EXPOSURE DETAIL, 47	DE-16484, 74
C-16478, 47	DE-16485, 75
Clinical Management Description, 69	DE-16524, 50
Clinical Manifestation Values, 18	DE-16525, 52
Comment, 13, 72	DE-16547, 54
В	DE-16548, 55
D	DE-16549, 56
Data Element	DE-16551, 57
Absolute Contraindication, 12	DE-16552, 58
Adverse Reaction Certainty, 21	DE-16553, 59
Adverse Reaction Comment, 13	DE-16631, 71
Adverse Reaction Event Comment, 72	DE-16634, 68
Adverse Reaction Instance Identifier, 80	DE-16693, 90, 115
Adverse Reaction Report, 74	DE-16697, 80
Anatomical Location Aspect, 38	DE-16698, 82, 107
Anatomical Location Description, 41	DE-16699, 85, 110
Anatomical Location Image, 43	DE-16700, 89, 114
Anatomical Diago 35	DE-16712, 105
Anatomical Plane, 35	Detailed Clinical Model Identifier, 90, 115
Anatomical Site, 64 Clinical Management Description, 69	Distance From Landmark, 40
Clinical Management Description, 69	Dose Duration, 67
DE-10145, 49 DE-10147, 62	Dose Unit, 50
DE-10147, 62 DE-10156, 64	Duration of Exposure, 46
DE-10156, 64	Duration of Reaction, 26
DE-15507, 25 DE-15521, 10	Earliest Exposure, 45
DE-15521, 10	

Exclusion Statement - Adverse Reactions In-	SPECIFIC LOCATION, 28
stance Identifier, 105	SUBJECT, 78, 103
Exposure Description, 44	TIMING, 53
Global Statement, 95	Date, 59
Identified Landmark, 37	Day of Month, 58
Intervention Date, 59	Day of Week, 57
Intervention Day of Month, 58	Delivery Method, 66
Intervention Day of Week, 57	Description, 41
Intervention Frequency Range, 54	Detailed Clinical Model Identifier, 90, 115
Intervention Interval Range, 55	Distance From Landmark, 40
Intervention Time, 56	Dose Duration, 67
Intravenous Administration Details, 68	Dose Unit, 50
Link Nature, 82, 107	Dose Unit Reference Set, 51
Link Role, 85, 110	Duration of Exposure, 46
Link Target, 89, 114	Duration of Reaction, 26
Manifestation, 17	
Medication Delivery Method, 66	E
Multimedia, 70	Earliest Exposure, 45
No Known Adverse Reaction to, 97	EXCLUSION STATEMENT - ADVERSE REAC-
No Known Allergic Reaction to, 98	TIONS, 93
No Known Hypersensitivity Reaction to, 99	Exclusion Statement - Adverse Reactions Instance
No Known Intolerance to, 100	
Numerical Identifier, 33	Identifier, 105
Quantity, 49	Exposure Description, 44
Quantity Description, 52	_
Reaction Description, 24	F
Reaction Onset Date, 25	Frequency Range, 54
Reaction Reported, 73	G
	•
Reaction Type, 19	Clobal Statement 05
Reporting Details, 71	Global Statement, 95
Reporting Details, 71 Route, 62	Global Statement, 95 Global Statement Values, 96
Reporting Details, 71 Route, 62 Side, 31	Global Statement Values, 96
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16	Global Statement Values, 96
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10	Global Statement Values, 96
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75	Global Statement Values, 96
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42	Global Statement Values, 96  I Identified Landmark, 37
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group	Global Statement Values, 96  I Identified Landmark, 37 Image, 43
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16341, 36	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16341, 36 DG-16423, 48	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68 L Laterality Reference Set, 32
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16341, 36 DG-16423, 48 DG-16431, 53	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68 L Laterality Reference Set, 32 LINK, 81, 106
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16423, 48 DG-16423, 48 DG-16474, 14	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16423, 48 DG-16423, 48 DG-16421, 53 DG-16474, 14 DG-16692, 81, 106	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107 Link Nature Values, 83, 108
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16423, 48 DG-16423, 48 DG-16474, 14 DG-16692, 81, 106 EXCLUSION STATEMENT - ADVERSE REAC-	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107 Link Nature Values, 83, 108 Link Role, 85, 110
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16423, 48 DG-16423, 48 DG-16474, 14 DG-16692, 81, 106 EXCLUSION STATEMENT - ADVERSE REACTIONS, 93	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107 Link Nature Values, 83, 108
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16341, 36 DG-16423, 48 DG-16431, 53 DG-16474, 14 DG-16692, 81, 106 EXCLUSION STATEMENT - ADVERSE REACTIONS, 93 INFORMATION PROVIDER, 76, 101	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107 Link Nature Values, 83, 108 Link Role, 85, 110
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16341, 36 DG-16423, 48 DG-16423, 48 DG-16474, 14 DG-16692, 81, 106 EXCLUSION STATEMENT - ADVERSE REACTIONS, 93 INFORMATION PROVIDER, 76, 101 LINK, 81, 106	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107 Link Nature Values, 83, 108 Link Role, 85, 110 Link Role Values, 87, 112
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16341, 36 DG-16423, 48 DG-16431, 53 DG-16474, 14 DG-16692, 81, 106 EXCLUSION STATEMENT - ADVERSE REACTIONS, 93 INFORMATION PROVIDER, 76, 101 LINK, 81, 106 MEDICATION ADMINISTRATION, 60	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Day of Week, 57 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107 Link Nature Values, 83, 108 Link Role, 85, 110 Link Role Values, 87, 112 Link Target, 89, 114
Reporting Details, 71 Route, 62 Side, 31 Specific Substance/Agent, 16 Substance/Agent, 10 Supporting Clinical Record Information, 75 Visual Markings/Orientation, 42 Data Group ADVERSE REACTION, 6 AMOUNT OF MEDICATION, 48 ANATOMICAL LOCATION, 27 DG-10108, 60 DG-10296, 76, 78, 101, 103 DG-15517, 6 DG-16137, 93 DG-16150, 27 DG-16151, 28 DG-16341, 36 DG-16423, 48 DG-16423, 48 DG-16474, 14 DG-16692, 81, 106 EXCLUSION STATEMENT - ADVERSE REACTIONS, 93 INFORMATION PROVIDER, 76, 101 LINK, 81, 106	I Identified Landmark, 37 Image, 43 INFORMATION PROVIDER, 76, 101 Interval Range, 55 Intervention Date, 59 Intervention Day of Month, 58 Intervention Frequency Range, 54 Intervention Interval Range, 55 Intervention Time, 56 Intravenous Administration Details, 68 Intravenous Details, 68  L Laterality Reference Set, 32 LINK, 81, 106 Link Nature, 82, 107 Link Nature Values, 83, 108 Link Role, 85, 110 Link Role Values, 87, 112

nehta Index

MEDICATION ADMINISTRATION, 60 Medication Delivery Method, 66 Multimedia, 70

#### N

Name of Location, 29 No Known Adverse Reaction to, 97 No Known Allergic Reaction to, 98 No Known Hypersensitivity Reaction to, 99 No Known Intolerance to, 100 Numerical Identifier, 33

#### 0

Onset of Reaction, 25

#### 0

Quantity, 49 Quantity Description, 52

#### R

Reaction Description, 24
REACTION EVENT, 14
Reaction Onset Date, 25
Reaction Reported, 73
Reaction Type, 19
RELATIVE LOCATION, 36
Reporting Details, 71
Route, 62
Route of Administration Reference Set, 63

#### S

Side, 31
Site, 64
SPECIFIC LOCATION, 28
Specific Substance/Agent, 16
SUBJECT, 78, 103
Substance/Agent, 10
Substance/Agent Values, 11
Supporting Clinical Record Information, 75

#### T

Time, 56 TIMING, 53

#### V

Value Domain
Adverse Reaction Certainty Values, 22
Body Structure Foundation Reference Set, 30, 65
Clinical Manifestation Values, 18
Dose Unit Reference Set, 51
Global Statement Values, 96
Laterality Reference Set, 32
Link Nature Values, 83, 108
Link Role Values, 87, 112
Route of Administration Reference Set, 63

Substance/Agent Values, 11 VD-10147, 63 VD-15521, 11 VD-15564, 18 VD-15568, 22 VD-16152, 30, 65 VD-16299, 96 VD-16312, 32 VD-16523, 51 VD-16698, 83, 108 VD-16699, 87, 112 Visual Markings/Orientation, 42

143

This page is intentionally left blank.